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ABSTRACT
STUDIES ON CYCLOOXYGENASE-1, ITS SPLICE VARIANTS, AND
MODULATION OF CYCLOOXYGENASE-2 BY INDUCIBLE NITRIC OXIDE
SYNTHASE AND NOVEL PHYTOCHEMICALS

Yibing Xu
Department of Chemistry and Biochemistry
Doctor of Philosophy

Cyclooxygenases (COXs) are of important therapeutic value as they are the target
site of aspirin-like drugs. Here I report nine new COX-1 splice variants in chapter 1,
which I characterized with regard to heme-binding and other properties.
Inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) are co-inducible
in many tissues following mitogenic and proinflammatory stimulation. In chapter 2, I
investigate the physical and enzymatic properties of human COX-2 and iNOS and
demonstrate that, despite reports to the contrary by another laboratory, they do not
interact.
The only reported COX-1 splice variant to exhibit cyclooxygenase activity has
been isolated from dog brain and is termed COX-3. It contains an in-frame insertion of
intron 1. However the existence of human COX-3 remains questionable since intron 1 is
out of frame. Two putative in-frame human COX-3 isozymes, COX-1b2 and COX-1b3,
(herein designated as COX-3-72 and COX-3-50) have been reported in the literature, but

only one of them, COX-3-72, has been characterized. In chapter 3, COX-3-50 and
COX-3-72 are reported to be over-expressed and determined to be active
cyclooxygenases. COX-3-72 and, to a greater extent, COX-3-50, were stimulated by
rofecoxib at physiological concentrations. A similar rofecoxib-stimulated COX activity
is observed in quiescent A549 cells. Immunoblot and immunoprecipitation analysis
suggest that human platelet and potentially A549 cells, contain a COX-3-50 like protein.
Lonicera japonica is used as an anti-inflammatory treatment in traditional
Chinese medicine. Its working mechanism is not well known. In chapter 4, I report that
extracts from this herb inhibit COX-2 by three mechanisms: direct inhibition,
transcriptional and post-transcriptional down regulation.
COX-1 and COX-2 are similar to each other in their crystallographic structures.
One of the most striking differences is that there are eight amino acids immediately
following the signal peptide in COX-1 which are not found in COX-2. The function of
this sequence is unknown. In chapter 5, I found that deletion of these amino acids
decreased COX-1 Vmax by approximately 4-fold, but had little effect on other properties
of the enzyme.
Selecting bacteria transformed with recombinant plasmids is a laborious step in
gene cloning experiments. This selection process is even more tedious when large
numbers of clones need to be screened. In appendix I, I describe an ultra fast plasmid
screening method. This new method was frequently used in the experiments performed
in chapters 2-6.
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General Introduction
Cyclooxygenases
Cyclooxygenases are encoded by two genes: COX-1 and COX-2. COX-1 is a
largely constitutive expressed gene, whereas COX-2 is highly inducible (1, 2).
Prostaglandins are a group of biologically active compounds that are oxidatively
metabolized from arachidonic acid (AA). They play important roles in human
physiology in both health and disease (1). COX isozymes catalyze the first step in
producing prostaglandins by synthesizing endoperoxide containing prostaglandin G2
(PGG2). PGG2 is then converted to PGH2 by the peroxidase site of cyclooxygenases.
PGH2 is not stable and is further metabolized to different bioactive prostaglandins (Fig G1). NSAIDs are inhibitors of cyclooxygenases. Except for aspirin, which acetylates
serine 530 of COX-1 and an analogous serine in COX-2, NSAIDs compete with AA for
binding in the COX active site to inhibit COX-1 and COX-2 (1, 3).
Fig. G-1. The arachidonic acid cascade. The
fate of arachidonic acid in cells is taken from
Simmons et al. (1). Arachidonic acid is
metabolized by lipoxygenases to HETEs and
HPETEs or by cyclooxygenases to PGH2
through PGG2. NSAIDs block the synthesis of
prostaglandin G2. Prostaglandin H2
spontaneously rearranges or is enzymatically
isomerized, oxidized, or reduced to yield
bioactive prostaglandin isomers.

1

COX-1 and COX-2 in all species are each about 600 amino acids in size (1).
COX-1 and COX-2 share about 60% amino acid identity in all species and have very
similar crystallographic structures. A gene duplication event gave rise to these
paralogous COX isoforms early in or prior to vertebrate speciation (4). In humans, the
COX-1 gene is located on chromosome 9q32–q33.3 and COX-2 is on chromosome
1q25.2–q25.3 (1). There are 11 exons and 10 introns in the human COX-1 gene, while
COX-2 has 10 exons and 9 introns. Both genes share conserved intron/exon boundaries
except for the presence of an extra intron inserted at the 5’ end of the COX-1 gene (intron
1). Intron 1 is located in the N-terminal signal peptide of the protein. COX-1 and COX2 also contain the same four functional regions: signal peptide, dimerization domain,
membrane binding domain and catalytic domain (Fig. G-2). The catalytic domain
contains both a cyclooxygenase active site and a peroxidase active site. In COX-1, the
signal peptide is encoded by exon 1 and 2, while the dimerization domain is encoded by
exon 3. Exon 4 encodes the membrane binding domain and exons 6-11 encode the
catalytic domain. The effect of alternative splicing on COX structure and activity is
predictable based on the relationship between exons and protein domains (1, 3, 4).
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Fig. G-2. Crystallographic structures of ovine COX-1 (left) and murine COX-2 (right) homodimers.
The crystallographic structure of ovine COX-1 and the murine COX-2 structure were from Protein Data
Bank file 1PRH and file COX5 (5, 6). Functional domains are shown in different colors: 1) membrane
binding domain (yellow); 2) dimerization domain (green); catalytic domain (blue) heme (red). The open
cleft of the peroxidase active site is observable at the top of each monomer.

COX-2 and iNOS
In addition to the potential of affecting COX activity by altering domains of COX
by splicing, COX activity can also be altered by protein-protein interactions. Inducible
NO synthase (iNOS) and cyclooxygenase-2 (COX-2) are co-inducible in many tissues
following mitogenic and proinflammatory stimulation (7). Although nitric oxide (NO)
does not bind COX heme (7), it can potentially modulate COX activity through
nitrosylation of cysteines (8, 9). The question of whether or not cross-talk occurs
between iNOS and COX-2 has been the subject of intense debate (10). COX-2 activity
and expression is regulated by NO, and iNOS protein expression is also influenced by
prostanoids, the products of COX-1 and COX-2. NO and its effector cyclic GMP
regulate the function of several down stream target proteins, including transcription
factors such as nuclear factor NF-κB and activator protein-1. This is the key pathway by
which NO may influence COX-2 expression (11).
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Alternative splicing
Approximately 1×105 different proteins are expressed in human cells, yet our
genome contains approximately 1/3 that number of genes. Proteome diversity is
achieved in part by alternative splicing of over sixty percent of transcribed genes in
humans (12). Alternative splicing not only leads to the expression of protein isoforms
but can also regulate mRNA translation and stability. It can control localization as about
twenty percent of alternative splicing happens in untranslated regions (13, 14).
Alternative splicing is required for apoptosis, sex determination, axon guidance, cell
excitation and contraction, and many other cellular and developmental processes (15).
Many diseases, such as growth hormone deficiency, Frasier syndrome, Parkinson’s
disease, cystic fibrosis, retinitis pigmentosa, spinal muscular atrophy, and myotonic
dystrophy are thought to involve alternative splicing in their pathogenesis (16). In recent
years, some cancer specific alternative splicing events have been reported without
genomic mutations, involving transcription factors, cell signal transducers, and
components of the extracellular matrix (17).
There are seven types of alternative splicing in mRNA (4): alternative exons may
be included with constitutive exons (Fig. G-3-1); exon switching may happen between
two alternative exons in transcripts (Fig. G-3-2); part of an exon, either 5’ end or 3’ end,
may be removed (Fig. G-3-3 and Fig. G-3-4); and alternative promoters or alternative
polyadenylation may also occur (Fig. G-3-5 and Fig. G-3-6). Finally, intron sequences
(Fig. G-3-7) may be retained in some transcripts. Intron retention is very important in the
cyclooxygenases’ gene regulation and expression.
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Fig. G-3. Alternative splicing in eukaryotes. The figure is taken from Roos et al. and revised (4).
Constitutive exons are shown as blue boxes, alternative exon cassettes are shown as yellow boxes. A
retained intron is indicated by a red box. Splicing is indicated by white lines, the upper set indicating
default splicing and the lower set indicating alternative splicing.

Prior to this work, a limited number of COX splice variants were known. This
dissertation addresses the biochemical and structural properties of many new COX-1
splice variants isolated from human tissue. The role of the amino terminal end of the
COX-1 protein is specifically explored in studies of potential human COX-3 splice
variants that retain an additional 31 amino acids on their N-termini, relative to COX-1.
Another study addresses the role of 8 amino acids found at the N-termini of COX-1 that
are not present in COX-2. In addition to these studies on COX-1, this dissertation
evaluates COX-2’s potential interaction with iNOS in human cells, and reaches a
conclusion that challenges an existing paradigm that these proteins physically interact in
cells. Finally, COX-2 selective inhibitions are important pharmacological treatments for
inflammatory disease. Here, honeysuckle extracts, are reported to contain compounds
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that, in addition to acting as COX-2 inhibitors, down-regulate COX-2 expression at the
transcriptional and post-transcriptional levels.
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CHAPTER 1
The effects of exon skipping on heme-binding, glycosylation, and catalytic activities
of human cyclooxygenase-1 splice variants
Abstract
Cyclooxygenases (COX) are encoded by two genes, COX-1 and COX-2. Four
COX-1 splice variants and two COX-2 splice variants are known. Here nine new COX-1
splice variants are identified by screening human cDNA libraries, and by doing RT-PCR
analysis of human cells and tissues. Each new variant involved some form of exon
skipping or intron retention. A dichotomy exists between COX-1 and COX-2 splice
variants in that the former, but not latter, produce potential heme-binding proteins that
could be enzymatically active. These studies address this question. When expressed in
insect and mammalian cell systems, glysosylation was observed with all new found
COX-1 splice variants except one which is not expected to enter the endoplasmic
reticulum, while no prostaglandins were formed by any new variants as determined by
radioimmunoassay, HPLC and TLC assays. Heme-binding and peroxidase activity were
easily detected in microsome preparations from insect cells infected with viruses
encoding COX-1, COX-2 and selected COX-1 splice variants. Co-expression of one
variant (Ex5) with COX-1 stimulated COX-1 cyclooxygenase activity. We conclude that
some of the new reported human COX-1 alternative splice variants are transcribed at
significant levels in specific cells or tissues, bind heme, contain residual peroxidase
activity, and may activate or otherwise influence COX activity.
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Introduction
Cyclooxygenases (COXs) are important therapeutic targets of aspirin-like drugs
and are encoded by two genes: COX-1 and COX-2. COX-1 is a largely constitutive
“housekeeping” gene, whereas COX-2 is highly inducible (1, 2).
Recent work lead to the identification of a canine COX-1 splice variant, termed
COX-3 (also known as COX-1b) that retains intron 1. COX-3 produces a novel
enzymatically active COX enzyme when ectopically expressed in insect cells (2). This
enzyme is more potently inhibited by some NSAIDs and analgesics, such as
acetaminophen and dipyrone, than mouse COX-1 and COX-2.
Another alternatively spliced COX-1 mRNA was isolated from a human lung
tumor and contains a deletion of part of exon 9 (3). This deletion eliminates an Nglycosylation site at residue 409, which is essential for proper folding of the enzyme and
enzyme activity. Consistent with this fact, this variant possesses no prostaglandin
synthesis activity. However, the sequence that provides the proximal histidine ligand to
heme is not deleted in this variant, suggesting the possibility of heme binding and
catalytic activity. A second COX-1 alternative splice variant was found in the EGV-6 rat
tracheal cell line (4). This variant has been proposed to arise from a putative alternative
promoter in intron 2 and encodes a predicted nonsense protein.
Two other COX-1 splice variants, Partial COX or PCOX proteins, exhibiting
exon skipping were found in canine brain and lack exons 5 through 8. This deletion
removes part (219 amino acids) of the globular catalytic region that contains both the
cyclooxygenase and peroxidase active sites (2). However, like the partial exon 9 deletion
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above, these proteins retain the proximal ligand to heme. The PCOX-1 forms are PCOX1a and PCOX-1b, where PCOX-1a also retains intron-1 which is absent in PCOX-1b.
Thus, five COX-1 splice variants have been reported to date from three different
mammalian species and four of these have the potential to bind heme, but all, except for
COX-3, lack cyclooxygenase activity.
Alternative splicing is also observed for COX-2 and the first example of COX
alternative splicing was the report of retention of intron 1 in the COX-2 mRNA (5).
More recently, a COX-2 variant, designated COX-2a, has been found that differs from
the human COX-2 sequence by a deletion of part of exon 5 (from position +458 to +567)
(6). This introduces a frame shift in the COX-2a sequence resulting in a TAA stop codon
at position +490. COX-2a is elevated in platelets isolated from patients after coronary
artery bypass grafting. A second splice variant, COX-2b, was identified in myometrium
from women in labor and in rat macrophage mRNA (7). This splice variant retains intron
7 sequence, which also introduces a frame-shift that deletes most of the COX-2 catalytic
domain. COX-2a and COX-2b lack catalytic domains and cannot possess activity as
cyclooxygenases or peroxidases, but may have regulatory roles in the cell through
heterodimerization with COX-2 via their dimerization domains.
A dichotomy therefore exists between COX-1 and COX-2 in that most splice
variants of the former have the potential to produce heme-binding proteins that could be
enzymatically active, whereas variants of the latter lack cyclooxygenase catalytic
domains. By analyzing RNA from a variety of human tissues and cells, we have
investigated exon-skipping in human COX-1 transcripts. Here we report new human
COX-1 splice variants, many of which fit stringent criteria for biological and
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pharmacological relevance: 1) they are expressed at significant levels in specific human
cells or tissues and, in some cases, are inducible; 2) they encode COX-like proteins that
are readily expressed in ectopic systems; 3) ectopically expressed proteins bind
membrane, target either to the lumen of endoplasmic reticulum where they are Nglycosylated or to the cytosolic surface of that organelle; and 4) these proteins bind heme
and have residual peroxidase activity.
Materials and Methods
Unless otherwise stated all basic protocols used were from the Manual on
Molecular Cloning by Sambrook and Russell (8).
cDNA library construction and screening, RT-PCR amplification, and DNA
sequencing. Isolation of RNA, library construction, and screening methods have been
described elsewhere (9). Briefly, human cDNA was synthesized from mRNA isolated
from ovarian tumor samples and freshly drawn peripheral blood mononuclear cell
(PBMC). For reverse transcription-coupled polymerase chain reaction (RT-PCR)
analysis, primers were designed for amplification of the COX-1 coding region. The
sense primer (5'-CTGCGTCCCGCACCCCAGCA-3') corresponded to nucleotides -20 to
-8 of the human COX-1 sequence. The antisense primer (5'TCAGAGCTCTGTGGATGGTCGCTCCACAGC -3') corresponded to nucleotides 17681799, ending at the stop codon. Amplicons were cloned into pCR2.1-TOPO and
transformed into competent E. coli (Invitrogen), and plasmids were isolated and
amplicons were verified by DNA sequencing.
For analysis of variants from human brain, poly (A) RNA (2.5ug) (Ambion) was
reversed transcribed with oligo dT and the cDNA was PCR amplified using the same
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primers described above. A library of these amplicons was then constructed in the vector
Lambda Zap II (Invitrogen). To isolate variants with skipped exons, duplicate filters of
the amplified library were differentially screened with 32P labeled human COX-1 cDNA
or with 32P labeled oligonucleotides corresponding to specific COX-1 exons. Plaques
that hybridized to COX-1 but not to the exon specific oligonucleotides were isolated,
plaque purified, in vivo excised and sequenced. Multiple screenings of the library were
carried out with oligonucleotides specific for exons five, six and eight.
Expression of COX-1 variants in Sf9 cells and COS-7 cells. For ectopic
expression and assessment of enzyme activity of COX-1 variants in Sf9 cells, complete
coding regions, verified by DNA sequencing, were cloned into the baculovirus
expression vector pBlueBac 4.5/V5-His according to the manufacturer’s instructions
(Invitrogen). For analysis of protein expression, Sf9 cells (~1 × 106) were infected with
viral stocks at a multiplicity of infection (moi) of 3 (2).
In some cases, to assess N-glycosylation of individual splice variants,
tunicamycin was added to a final concentration of 10 µg/ml to insect cells 1 h after
infection. Cells were then cultured and harvested after 48 h. Levels of recombinant
protein expression were determined by immunoblot analysis, and COX activity in intact
cells was determined by radioimmunoassay (RIA) (2), reverse phase high performance
liquid chromatography (HPLC) and thin layer chromatography (TLC).
For immunoblot analysis of protein expression, total protein (20 µg) from cells
was resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose
membrane, and probed with ovine COX-1 mAb (Cayman Chemical). Primary antibodies
(1:2,000) were incubated with membranes overnight. Blots were processed with
12

appropriate secondary antibody (1:2,000) from Sigma. Densitometry of the blot images
was performed using the AlphaImage 2000 Documentation and Analysis System (Alpha
Innotech, San Leandro, CA).
COX-1 and its splice variants cloned into the pcDNA3.1 vector were transiently
transfected into COS-7 cells using lipofectamine with Plus Reagent (Invitrogen). Cells
were harvested 48 h post-transfection by scraping, and were washed once with PBS. To
measure N-glycosylation of COX variants in mammalian cells, tunicamycin was added to
COS-7 cells to a final concentration of 10 µg/ml 4h after transfection. Cells were then
cultured for an additional 48 h. Assessments of COX-1 and splice variant expression and
activities were done by TLC and RIA using intact cells as described for insect cells
(above).
Cyclooxygenase activity assays.
a. Radioimmunoassay (RIA). Infected Sf9 cells (0.2 x 106 cells; 100µl) were
incubated with arachidonic acid (100 µl, 60 µM) for 15 minutes at 37°C. Supernatants
were assayed for COX activity by RIA for PGE2 as previously described (2). At least
three separate assays were performed for every protein analyzed and each was done in
triplicate.
b. Reverse Phase-HPLC. As described previously (10), infected Sf9 cells were
harvested and resuspended in buffer (100 mM Tris/HCl, 0.5 mM phenol, pH 8.0 and 1
µM hematin). Equal numbers of cells expressing approximately equal levels of protein,
as determined by immunoblotting, were used in each assay. Cells expressing COX-1 or
COX-1 variants were incubated with 0.25 µCi [uniformly labelled-14C] arachidonic acid
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in a total volume of 1ml for 20 min at 37°C. The reaction was terminated by adding 10µl
glacial acetic acid to a final pH of 4 and protein was precipitated by the addition of 2 ml
of acidified methanol and 125 µl of methylene chloride. Arachidonic acid and its
metabolites were extracted into ether (2x4 ml) and dried.
Products were analysed by reverse phase-HPLC using a Waters Symmetry C18 5
µm column (0.46 cm×25 cm) eluted at a flow rate of 1 ml/minute with the following
solvents: methanol/water/acetic acid (60:40:0.01, v/v) for 10 minutes. This was followed
by increasing methanol up to 100% (100:0:0.01) for 20 minutes followed by acidified
methanol for 10 min. Fractions were collected every 12 sec and quantified using a liquid
scintillation counter (Tri-CARB 2100 TR).
c. Thin-layer chromatography (TLC). As described before (11, 12), infected
Sf9 cells or transfected COS-7 cells were incubated with 0.75 µCi [ uniformly labled-14C
] arachidonic acid for 30 min at 37 °C and reactions were terminated by addition of acetic
acid to pH 4. Arachidonic acid products released into the incubation medium were
isolated through chromatography on reverse phase Sep-Pak columns (Waters) and the
eluted products were dried and resuspended in methanol. For each assay, equal amounts
of radioactive products were applied on loading strips of Whatman linear-K preadsorbent
TLC plates. Chromatograms were developed using the upper organic phase of an ethyl
acetate/ 2, 2, 4-trimethylpentane/ acetic acid/ water mixture (165:75:30:150, v/v/v/v)
which was shaken and then resolved in a separation flask. Plates were air dried (5 min)
under vacuum (75°C, 10 min) to remove residual solvent and were exposed overnight to
X-ray film (XB-1, Kodak).
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Heme binding assays. Sf9 cells were infected with high titer viral stocks
(moi = 3) and cultured for 48-72 hrs. Cells were scraped, sedimented to remove tissue
culture media, and rinsed in phosphate buffered saline (PBS) with protease inhibitors (PI)
(Roche, Germany). Equal aliquots (2 × 107 cells) of COX-1, COX-2 or of each variant
were resuspended in 5 ml of PBS. Hematin (50 µl, 2 mM) was added and cells were
incubated at 37°C for 1 hr. Unbound hematin was removed by washing the cells twice in
5 ml of PBS. Washed cells (5 ml) were then suspended in glass test tubes and
photographed. Photographs were analyzed for color density using AphaDigiDoc
software (Alpha Innotech). Intracellular hematin was then extracted and measured (13,
14). Washed cell pellets were suspended in acidified acetone (1 ml) by vigorous
vortexing and allowed to incubate on ice for two hours. Water and ether (1 ml of each)
were then added and the heme extracted into the ether layer. The ether fraction was then
washed with 200 µl of 5% NaCl in water. Phosphate buffer, 1 ml at pH 8.0, was then
added, and the organic fraction removed and evaporated to dryness at 56°C. Extracted
heme was resuspended in 100 µl of pyridine to which was added 1 µl of 0.1 M
K2Fe(CN)6, 100 µl of 0.2 M NaOH, 100 µl of 40% pyridine and 6mg of solid sodium
thionite. The concentration of heme was measured spectrophotometrically at an
absorbance of 584 nm. The same experiment was performed on subcellular fractions of
cells derived through sonication to evoke lysis followed by differential centrifugation to
isolate nuclei (1000 x g for 10 minutes), mitochondria (10,000 x g for 20 minutes), and
cytosol containing microsome (the supernatant of the mitochondria preparation).
Heme bound to protein was also measured by low temperature electron
paramagnetic resonance spectrometry (EPR). Cells were first treated with hematin and
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washed as described above. The cells were then gently sedimented in EPR tubes, media
was removed, and the cells flash frozen. EPR spectra were obtained with a Bruker E500
spectrometer at 4° K.
Peroxidase assays. For peroxidase assays, Sf9 cells were infected with viral
stocks (moi = 3) and cultured for 48 to 72 hrs. Five different assays, employing different
co-reductants, were used to test for the peroxidase activity of COX-1 variants.
Microsomal protein (200 µg) from infected Sf9 cells was added in each of the 5 assays to
a microcuvette (1 cm path length) containing 500 µl of 100 mM Tris/HCl, 0.5 mM
phenol (pH 8.0), hematin (1 µM final) and 200 µM ABTS. After 1 min of equilibration,
the reaction was initiated by the addition of 1 µl of 20 mM H2O2. The reaction was
recorded spectrophotometrically (417 nm) at room temperature for 10 min.
The tetramethylphenyldiamine (TMPD) peroxidase assay was performed as
described by Kulmacz et al., 1987 (15). Briefly, microsomes were prepared, resuspended
in 150 µl of PBS containing 1 µM hematin followed by incubation at 37ºC for 30 min.
The reaction cocktail contained 0.1 M Tris (pH 8.0), 0.2 mM TMPD, 9 µM H2O2 and 200
µg total microsomal protein. The reaction was initiated by the addition of H2O2.
Oxidation of TMPD was then spectrophotometrically measured at an absorbance of 610
nm for 10 min.
The guaicol peroxidase assay was performed on microsomes prepared as
described above (16). The reaction cocktail contained 1 ml of 0.1 M sodium phosphate
(pH 7.0), 5 mM guaicol, 60 µm H2O2, and 200 µg total microsomal protein. Absorbance
was read at 480 nm for 10 min at room temperature. In one experiment, stopped flow
analysis was used to analyze peroxidase activity by this method.
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The 10-acetyl-3, 7-dihydroxyphenoxazine assay (17) reaction was done in a final
volume of 1ml containing 200 µg microsomal protein, 0.1 M Tris, pH 8.0, 9 µM H2O2,
and 50 µg 10-acetyl-3, 7-dihydroxyphenoxazine. The reaction was incubated at room
temperature for 30 minutes and fluorescence was measured at an excitation of 560 nm
with emission detection at 590 nm.
The Amplex Red Hydrogen Peroxide Assay (Molecular Probes; Eugene, Oregon)
was performed exactly as described by the manufacturer. This assay differs from those
above in that, rather than directly quantifying the co-reduction of substrates by COX-1
variants as a measurement of peroxidase activity, it measures the amount of hydrogen
peroxide that remains in a reaction cocktail following incubation with 200 µg of
microsomal protein. The assay is also described in detail by Votyakova et al. (18).
Ex5 and COX-1 co-expression assays. Sf9 cells (~5 × 106) were simultaneously
infected with Ex5 and COX-1 viral stocks of an MOI of 3 to co-express those two
proteins. Cells were collected after 48 h infection for Western blot and RIA.
Results
Characterization of COX-1 alternative splicing variants. By constructing and
screening human cDNA libraries, and by doing RT-PCR analysis of human cells and
tissues, we identified nine COX-1 variants which are expressed at significant levels in a
cell specific fashion (Fig.G-1). Each new variant involved some form of exon skipping
including: skipping of exons 2-3 (Ex2-3); skipping of exon 3 (Ex3), skipping of exon 3
and part of exon 9 (Ex3+ExP9); skipping of exon 5 (Ex5); skipping of exons 3-5 and part
of exon 9 (Ex3-5+ExP9); skipping of exons 3-8 (Ex3-8); skipping of exons 3-9 (Ex3-9);
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skipping of exon 10 (Ex10); skipping of exon 3 and retention of intron 1 (Intron1+ Ex3).
These new COX-1 splice variants are summarized in Figure 1-1.

Fig. 1-1. Diagrammatic representation of human COX-1 and COX-1 splice variants. Exons are
denoted in different shading, and skipped exon deletions are shown by dots. Retained introns are indicated
by a solid black line. The 5.2kb variant is a fully processed COX-1 mRNA resulting from alternative
polyadenylation. COX-3, Intron 2 and Intron 1+Ex3 have retained introns. Exon skipping is observed in
Ex2-3, Ex3, Ex5, Ex3-8, Ex3-9, and Ex10. ExP9, Ex3+ExP9 and Ex3-5+ExP9 have part of exon 9 being
removed.

Some of the variants described here were transcribed at higher levels than others
in human cells. As a representative example, COX-1 was amplified from human PBL
cDNA. The resulting fragments were cloned in pcDNA3.1 (Invitrogen) and then
screened for COX-1 as described (2). Thirty clones that hybridized to a COX-1 probe
were isolated and subsequently characterized by automated DNA sequencing. Five of the
thirty clones were found to be ExP9 which has been previously isolated by others (3).
Five clones were found to be Ex3, and one clone was Ex3+ExP9. Thus, assuming equal
amplification, the mRNA levels of individual COX-1 splice variants individually
constitute 3-17% of COX-1 transcripts, with all the variants together constituting roughly
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38% of total COX-1 transcripts (data not shown). In some cases, splice variants were
inducible. In explanted PBL cells, Ex3+ExP9 was induced at levels that exceeded COX1 by the treatment of interleukin-1β (IL-1β) or with a mixture of IL-1β , TNFα and IFNγ
(cytomix) other pro-inflammatory mediators for 36 hours (Fig. 1-2a).
Some of the variant mRNAs are expressed in a marked tissue specific fashion. Of
the tissue and cells being examined, Ex5 was only present in human ovarian tissue and
ovarian cancer specimens. Analysis by RT-PCR indicated that the mRNA level of the
Ex5 splice variant in human ovarian tissue and ovarian cancer specimens is about 1020% of the level of COX-1 mRNA as determined by densitometry using the AlphaImage
2000 Documentation and Analysis System, and no difference in expression level was
observed between ovarian tumors, ovarian benign tumor and ovarian normal tissue (Fig. 1
-2b). In contrast, Ex3-5+ExP9, Ex3-8, Ex3-9 and Ex10 have so far only been found in a
human brain cDNA library. However, ExP9 was found in all human tissue we screened.
Along with COX-3 mRNA and a splice variant that retains part of intron 2 (to be reported
elsewhere), the extra splice variant is commonly co-expressed with COX-1 in human
tissue and cell lines at about 10-20% of the level of COX-1 as determined by
densitometry.
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Fig. 1-2. PCR amplification of COX-1 and COX-1 variants. 2a: Variants in human PBL. PBL cells were
treated by cytomix (a mixture of IL-1β , TNFα and IFNγ) and IL-1β for 12 h or 36 h. Arrows indicate
COX-1 variants: ExP9 and Ex3 (upper); ExP9+Ex3 (lower). 2b: COX-1 splice variants in human ovarian
tissues. Lane 1-3, three ovarian tumors; lane 4, ovarian normal tissue; lane 5, ovarian benign tumor; lane 6,
COX-1 control; lane 7, COX-3 control. Arrows indicate COX-1 variants: COX-3 (upper); Ex5 (middle);
ExP9 (lower).

Ectopic expression of COX-1 splice variants in insect and mammalian cells.
COX enzymes are intralumenal residents of the endoplasmic reticulum and depend on Nlinked glycosylation for proper folding and activity. COX-1 and COX-2 have both been
successfully expressed in insect and mammalian cells systems. However, the activity of
COX-1 is frequently lower than that of COX-2 when expressed in insect cells (14). The
cause of this is unknown but may be due to differences between the two enzymes in
achieving proper folding in this system. Glycosylation and activity was, therefore,
measured for human COX-1 splice variants in both insect and mammalian cell systems.
Insect cells (Sf9) infected with recombinant baculovirus expressing COX-1, ExP9,
PCOX-1a and PCOX-1b and COS-7 cells transfected with COX-1, Ex3+ExP9, ExP9 and
Ex3 recombinant plasmids in pcDNA3.1 were assayed for protein expression by Western
blotting with a COX-1 monoclonal antibody and a COX-2 anti-peptide antibody. Based
on their observed levels of expression, most splice variants were expressed as efficiently
in these cell systems as COX-1 and COX-2 (Fig. 1-3). Posttranslational N-linked
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glycosylation of COX-1 variants was compared with that of COX-1 by using tunicamycin
to inhibit core glycosylation. All splice variants were predicted to be glycosylated except
Ex2-3, which lacks a functional N-terminal signal peptide. Immunoblot analysis
confirmed that COX-1 and its splice variants were all glycosylated, whether expressed in
insect or mammalian cells (Fig. 1-3a and 1-3b). The Ex2-3 variant was an exception to
this rule. Its expression was insensitive to tunicamycin. However, the Ex2-3 protein did
appear to experience posttranslational modification as evidenced by the fact that it
migrated as a doublet upon SDS-PAGE. In the course of our studies, we consistently
observed that the majority of COX-1 protein, and frequently that of its splice variants, is
expressed in a non-glycosylated form in insect cells (Fig. 1-3a). This is likely due to the
massive amounts of COX-1 protein produced in this cell system resulting either in
improper folding or a lack of translocation into the endoplasmic reticulum. We analyzed
canine COX-3 protein by mass spectrometry for post-translational modifications and
found that it was phosphorylated on Thr 165 (data not shown). Thus phosphorylation or
other events may be responsible for post-translational modification of Ex2-3.
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Fig. 1-3. Expression in insect and COS-7 cells. 3a: Immunoblots demonstrate the expression of COX1, Ex 9P, PCOX-1a, and PCOX-1b in insect cells treated with (+) and without (-) tunicamycin. Asterisks
indicate non-glycosylated COX-1 and other variants. The protein bands that migrate slower than the nonglycosylated proteins are modified forms of COX-1 and its splice variants. Arrows indicate modified
COX-1 and other variants which are not affected by the treatment of tunicamycin. Overexpression of
COX-1 and its variants consistently resulted in the detection of immunoreactive proteins that are smaller
than non-glycosylated COX forms (example indicated by brackets). These likely represent proteolytic
breakdown products or proteins resulting from incorrect initiation or termination of translation. 3b:
Immunoblots demonstrate the expression of COX-1, Ex3+ExP9, ExP9 and Ex3 in COS-7 cells treated with
(+) and without (-) tunicamycin.

Cyclooxygenase activity. Sf9 cells infected by COX-1 and COX-1 variants were
assayed for COX activity using RIA for PGE2. No cyclooxygenase activity was detected
for any tested COX-1 variant containing a skipped exon (Fig. 1-4a).
Sf9 insect cells infected with COX-1, COX-2, Ex2-3, Ex3, ExP9, Ex3+ExP9 Ex5,
Ex10, PCOX-1a and PCOX-1b were also measured by RP-HPLC for cyclooxygenase
activity by incubating whole Sf9 cells with [uniformly labeled -14C] arachidonic acid and
analyzing released prostaglandins by HPLC coupled to scintillation counting. COX-1
and COX-2 completely oxidatively metabolized the radio labeled arachidonic acid while
variants containing a skipped exon had no effect. Representative chromatograms
comparing COX-1 with PCOX-1b are shown (Fig. 1-4b).
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Fig. 1-4. RIA, Reverse phase-HPLC and TLC analysis of products formed by COX-1 and COX-1
variants. 4a: RIA assay of cyclooxygenase activity of COX-1 (positive control), Wild type baculovirus
infected cells (negative control), and selected COX-1 variants. No cyclooxygenase activity was shown on
COX-1 variants. 4b: Products from COX-1 and PCOX-1a were analyzed by reverse phase-HPLC.
Fractions were measured with a scintillation counter. Data (counts per minute) (y axis) are shown as a
function of elution time(x axis). 4c: An autoradiogram of thin-layer chromatography separation of the
products obtained after incubation of [uniformly-14C] arachidonic acid with Sf9 cells infected with COX-1,
COX-2, COX-3 and PCOX-1a. COX-1 and COX-2 show very high activities. COX-3 cyclooxygenase
activity is about 20% of COX-1. No cyclooxygenase activity was observed for PCOX-1a.

Thin layer chromatography (TLC) coupled with autoradiography was also done to
further confirm these results (Fig. 1-4c). In this analysis, canine COX-3 activity was
~20% of that of COX-1, which is consistent with RIA data previously published for this
COX-1 variant (8), whereas PCOX-1a lacked detectable COX activity. Thus, other than
COX-3, no COX-1 splice variants showed PG production as measured by these different
methods.
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Heme binding assays. Because of a negative finding for COX activity, Sf9 cells
expressing COX-1 splice variants were assessed for heme binding. When incubated in
the presence of exogenous heme, Sf9 cells expressing COX-1, COX-2 or COX-1 splice
variants became visibly brown compared to cells infected with wild-type virus or with a
virus encoding a non-heme protein, nucleobindin (unpublished data). The color density
of cell pellets was quantified by photography and densitometry (Fig. 1-5a). Intracellular
heme was then measured by extraction with organic solvent and found to be significantly
higher for COX-1, COX-2, and all tested COX-1 variants than for cells infected with wild
type virus (Fig. 1-5b). To determine whether this represented an increase in heme bound
to intracellular protein, rather than simply increased levels of free intracellular pools of
heme, cells expressing COX-1, Ex5 or wild type virus were treated with 20 µM hematin
for 30 minutes, vigorously washed to remove extracellular hematin, lysed by sonication,
and fractionated into nuclei, mitochondria, and cytosol containing microsomes. The
majority of heme was associated with the nuclear and mitochondrial membranous
fractions and was significantly elevated in cells expressing COX-1 and Ex5 versus wild
type virus (Fig. 1-5c).

24

25

Fig. 1-5. COX-1 variants and heme binding assays. 5a: The color density of exogenous heme bound to
Sf9 cells infected by wild type, COX-1, COX-2 and COX-1 splice variants virus were measured. COX-1
variants cell color density was significantly higher (T-test, *, p<0.05) than wild type cells. 5b: Intracellular
heme in wild-type-infected and recombinant expressed in Sf9 cells was extracted and measured. COX-1
variants contained significantly higher heme (T-test, *, p<0.05) than wild type cells. 5c: Heme bound to
nuclei, mitochondria, and cytosol containing microsomes was measured. The majority of heme was
associated with the nuclear and mitochondrial membranous fractions and was significantly elevated in cells
expressing COX-1 and Ex5 versus wild type virus (T-test, **, p<0.001). 5d: Low-temperature EPR data on
whole cells overexpressing COX-1 or PCOX-1. A specific resonance peak at roughly 1200 G as indicated
by arrows was observed for both COX-1 and PCOX-1b that is diagnostic of protein bound high spin ferric
heme. This peak was not observed in wild type cells or in a hematin solution.
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To further confirm that heme was protein bound, low-temperature EPR was
performed on whole cells overexpressing COX-1 or PCOX-1a. The latter possesses a
deletion of 219 amino acids in its catalytic domain from skipping of exons 5-8. This is
the largest deletion of any of the COX-1 variants evaluated and is predicted to have a
profound impact on the structure of the COX catalytic domain that could potentially
affect heme binding. A specific resonance peak at roughly 1200 G was observed for both
COX-1 and PCOX-1b that is diagnostic of protein bound ferric heme. This peak was not
observed in wild type cells or in a hematin solution (Fig. 1-5d).
Peroxidase assays. COX enzymes are evolutionarily derived from peroxidases
and possess distinct cyclooxygenase and peroxidase active sites. The dual finding that
COX-1 variants lack COX activity yet bind heme raised the question of whether they
might still possess peroxidase activity. Five different methods that employed different
co-reductants or strategies for measuring peroxidase activity were used to test the
peroxidase activity of COX-1 variants. TMPD, guaicol, 10-acetyl-3, 7dihydroxyphenoxazine and 2, 2'-azino-bis (3-ethylbenzthiazoline-6-sulphonic acid)
(ABTs) were employed as co-reductants (Fig. 1-6). To reduce confounding levels of
endogenous cellular peroxidase pools, assays were performed on isolated microsomes
from infected sf9 cells. Prior to assay, the level of expression of each variant in the
microsomal preparations were measured by immunoblotting in order to equalize the
amount of immunoreactive protein used in each assay. With H2O2 used as substrate and
TMPD, guaicol, 10-acetyl-3, 7-dihydroxyphenoxazine, or ABTs used as co-reductant, we
readily detected peroxidase activity of COX-1, COX-2, and COX-3, as would be
expected from their ability to synthesize prostaglandin H2 and its derivatives.
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Importantly, however, COX-1 variants also exhibited peroxidase activity. In many cases
these levels equaled or exceeded the activity of COX-1 and COX-2, but were coreductant dependent. For example, Ex3+ExP9, demonstrated peroxidase levels that were
comparable to COX controls when guaicol, 10-acetyl-3, 7-dihydroxyphenoxazine, or
ABTs were used as coreductants, but lower levels when TMPD was used. PCOX-1b,
however, consistently exhibited peroxidase activity that was greater than that of COX-1
in all assays that were employed.

Fig. 1-6. Peroxidase assays. Peroxidase activity of COX-1 variants was tested by three assays based on
absorbance (Fig.5a, Fig.5b and Fig.5c), two assays based on fluorescence (Fig. 6d, Fig. 6e) and one on
stopped flow coupling with absorbance(Fig. 6f). 6a: ABTS peroxidase assay. 6b: TMPD peroxidase
assay. 6c: Guaicol peroxidase assay. 6d: 10-acetyl-3, 7-dihydroxyphenoxazine peroxidase assay. 6e:
Amplex Red peroxidase assay. ABTS assay was measured at 470nm; TMPD peroxidase assay was
measured at 610 nm; guaicol peroxidase assay was measured at 480 nm; and the 10-acetyl-3, 7dihydroxyphenoxazine assay and the Amplex Red hydrogen peroxide assay were measured by excitation at
550nm and detection at 590nm, respectively. All of the COX-1 variants measured contain statistically
significant higher peroxidase activity than cells infected with wild type virus (T-test, *, p<0.05).
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Ex5 and COX-1 co-expression assays. The finding that COX-1 splice variants
lack COX activity but bind heme and possess a type of peroxidase activity suggested that
they could modulate COX activity either through heterodimerization or modulation of
redox tone. To test this, Ex5, which possesses the EGF module of the dimerization
domain, was co-infected with COX-1 into Sf9 cells and cyclooxygenase activity was
measured by RIA as a function of increasing Ex5 expression. Because COX-1
expression decreases with increasing Ex5 expression due to promoter competition, data
were normalized for the level of COX-1 protein. Co-expression of increasing amounts of
Ex5 with COX-1 produced a concomitant stimulation of COX-1 activity under saturating
levels of arachidonate substrate that peaked at more than two-fold that of COX-1 control
(Fig. 1-7).
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Fig. 1-7. Co-expression of Ex5 with COX-1 and increased COX-1 activity. Ex5 and COX-1 were coexpressed in Sf9 cells. Cyclooxygenase activity was measured and normalized for the level of COX-1
protein. Co-expression of increasing amounts of Ex5 with COX-1 produced a concomitant stimulation of
COX-1 activity under saturating levels of arachidonic acid that peaked at more than two-fold that of COX1 control (T-test, **, p<0.001). The data shown here represent three experiments.

Discussion
In these studies we show that human tissues and cells produce many more COX-1
splice variants than were previously known. All the splice variants that resulted from
exon skipping, except for Ex10 resulted in in-frame deletions producing proteins with
possible enzymatic function. Indeed, studies in other systems show that splice variants
can encode new proteins, new therapeutic targets, and new regulators of physiological
and developmental processes. However, the biological role and importance of splice
variants is unequivocally demonstrated by identifying, characterizing, or purifying the
protein product of the splice variant from tissues and cells. Thus far this has been
accomplished for relatively few splice variants of any gene. For shortlived, or nonabundant enzymes involved in signaling, such as COX enzymes, this is particularly
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difficult and is complicated by the fact that COX-1 and its variants are difficult to
dissociate and purify from membrane. Moreover, COX-1 splice variants are difficult to
detect by immunoblotting because many of them migrate in SDS-PAGE with proteolytic
breakdown products of COX. However, by immunoblotting techniques we have
previously identified expression of one of the most abundant of mammalian COX-1
splice variants, PCOX-1a, in dog brain (2). Its function, though, is unknown.
Biochemical data reported here suggest that human COX-1 splice variants are
biologically relevant. They are expressed at significant levels in cell- and tissue-specific
fashions, are in some cases inducible, bind heme, and, in one instance, they may
modulate COX-1 catalytic activity upon co-expression. As examples of biologically
relevant levels of expression, the human COX-1 ExP9 variant is found at about 10% of
the level of COX-1 in most of the human tissues and cell lines we have examined. Others
have shown that treatment of cultured human lung fibroblasts with transforming growth
factor β1, interleukin 1β, and tumor necrosis factor α cause a two fold up-regulation of
the ExP9 mRNA as compared to the intact COX-1 transcript (3). Additional human
variants reported here show more striking patterns of cell-specific expression or
inducibility (Fig. 1-2). For example, Ex5, was found only in normal ovarian tissue and
human epithelial ovarian tumor specimens (Fig. 1-2b). For unknown reasons, vertebrate
brain tissue is known to make many splice variants (2) and the same is true with regard to
splice variants of COX-1. PCOX-1a and PCOX-1b mRNAs were previously found in
high amounts in canine brain. In these studies we identified Ex3-5+ExP9, Ex3-8, Ex3-9
in human brain. Although expressed at lower levels than canine PCOX-1a and PCOX1b, these human variants were cloned from whole brain and it is possible that they are
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expressed at higher levels in specific regions of the brain, or in certain cells or
developmental stages. An example of marked induction was observed for the human
splice variant Ex3+ExP9, which was found to be highly elevated within 36 hours
following treatment with cytokines (a mixture of IL-1β , TNFα and IFNγ ) in PBMC. In
untreated cells, this splice variant was present at about 3% of the level of COX-1 mRNA
but increased following stimulation to levels that exceeded that of COX-1 (Fig. 1-2a).
Together these data suggest that splice variant expression is not haphazard or due to
faulty RNA processing, but instead reflects a biological role for these transcripts and their
translation products.
Our studies have previously noted that intron placement in COX genes demarks
boundaries of the major domains of these proteins (19). In COX-1, exons 1and 2 encode
the signal peptide, exon 3 encodes the EGF module that constitutes the majority of the
dimerization domain, exon 4 encodes the membrane binding domain, and exons 5-11
encode the catalytic domain with its two active sites (1). Skipping of exons 2-5 or exon
7 produces in-frame deletions of these structures as does the simultaneous skipping of
exons 6 and 8 (19). Skipping of a specific exon can evoke removal or alteration of proper
subcellular localization, membrane binding, dimerization etc. This is demonstrated by
Ex2-3 which lacks an amino terminal signal peptide and dimerization domain and is
predicted to be on the cytosolic surface of the endoplasmic reticulum or other membrane
structures. This was confirmed by subcellular fractionation and the demonstration that
Ex2-3 microsomal protein was insensitive to the action of tunicamycin (Fig. 1-3a).
However, higher molecular weight electrophoretic moieties of this protein were observed
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for this protein that likely reflect modifications other than N-linked glycosylation. We
have identified one such candidate in the phosphorylation of Thr 165.
One unusual finding of our studies was that nine out of the thirteen COX-1 splice
variants we have characterized (Fig. G-1) contain a deletion of either exon 3 or exon 5
which encode the dimerization domain. Exon 3 encodes the majority of this structure
(domain 1), which contains three disulfide bonds reminiscent of epidermal growth factor.
A fourth disulfide bond, in dimerization domain 2, encoded by exon 5, links the
dimerization domain with the globular catalytic domain (1). Theoretically, skipping
these exons, particularly exon 3, may produce monomers. This could prevent direct
binding of these variants to COX-1 where they could potentially act as direct modulators
of COX. However, our finding that the Ex-5 variant increases COX-1 catalytic activity
(Fig. 1-7) suggests that this is either not the case for splice variants containing deletion of
exon 5 or that these variants can alter COX activity in trans, potentially through altering
redox tone.
The finding that COX-1 splice variants bind heme was surprising for some of the
variants that contain deletions in their catalytic domains. Five separate assays detected
varying levels of the ability of these proteins to catalyze peroxide reduction (Fig. 1-6, ae). The peroxidase activities of splice variants were co-reductant dependent. Ironically,
PCOX-1a and PCOX-1b exhibited the highest activities in some of these assays even
though they contain the largest deletions in their active sites (Fig. 1-6, a-e). The degree
of peroxidase activity for each of these variants may differ from COX-1 or from each
other if lipid peroxides instead of hydrogen peroxide were used as substrate.
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A previous study done by Schneider et al. (20) did not detect peroxidase activity
of ExP9, which they attributed to the inability of the enzyme to bind heme cofactor.
However, they did not test this possibility. Our experiments, in contrast, show that ExP9
protein binds heme and possesses peroxidase activity, which varies with the co-substrate
used (Fig. 1-6, a-c). This discrepancy may be due to the fact that previous studies used
30µg of microsomal protein from COS-7 cells while we used 200µg of microsomal
protein from insect cells. Moreover, insect cells produce much more recombinant protein
than COS-7 cells and this proterty may further increase our ability to detect peroxidase
activity.
At present, it is unclear whether the elevated peroxidase activity associated with
expression of COX-1 splice variants represents the actual roles of these proteins in
nature. Apart from having detectable peroxidase activity, COX-1 variants described here
could possibly have other heme-mediated catalytic actions. Further studies, including
purification of individual COX-1 splice variants, are needed in order to fully define their
catalytic roles.
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CHAPTER 2
Inducible nitric oxide synthase-cyclooxygenase-2 interaction in human cells: An
unlikely pairing
Abstract
Inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) are coinduced in A549 human lung cells following treatment with endotoxin or cytokines.
Similar co-induction of iNOS and COX-2 in murine RAW cells has been reported to
result in physical interaction of the two proteins, causing activation of COX-2 via Snitrosylation. However, co-immunoprecipitation and enzyme activity studies do not
support this proposed interaction in human lung A549 cells as well as in human cell lines
from other tissue sources. The physical and enzymatic properties of COX-2 and iNOS
suggest that a lack of interaction is the rule in humans to which the murine findings may
be an exception.
Introduction
Inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) are co-inducible
in many tissues following mitogenic and proinflammatory stimulation. Although NO
does not bind COX heme (1), it can potentially modulate COX activity through
nitrosylation of cysteines (2, 3). The question of whether or not cross-talk occurs
between iNOS and COX-2 has been the subject of intense debate (4). Recently, Kim et
al. found that iNOS and COX-2 physically interact in LPS/ IFNγ- induced murine
macrophage RAW264.7 cells as well as when mouse iNOS and human COX-2 were
transfected into human embryonic kidney cells (HEK293T) (5). However, iNOS is a
cytosolic protein whereas COX-2 is an intralumenal resident of the endoplasmic
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reticulum (ER). They, therefore, are separated by an ER membrane making direct
contact unlikely (6). As previous results were in a murine system or used mouse iNOS,
we have analyzed human COX-2 and iNOS in HEK293T, human lung carcinoma cells
(A549 cells), Hela cells and Scupt 1 cells where they are co-transfected or coinduced by
IL-1β/LPS/ IFNγ. When analyzed by a variety of methods, human iNOS and COX-2 do
not interact, suggesting that any cross-talk between the two enzyme systems would need
to be mediated by diffusible products (i.e. NO and prostanoids) between the two enzyme
systems and not by enzyme contact.
Materials and methods
Cells. A549 and HEK293T cells were purchased from American Type Culture
Collection (Manassas, VA). Cells were maintained in F-12 nutrient mixture with 10%
fetal bovine serum (Hyclone, Logan, UT).
Reagents. Il-1β and IFN-γ were from Sigma; 1400W was from Alexis
Biochemicals (San Diego, CA); iNOS antibody was from BD Biosciences (Franklin
Lakes, NJ); COX-2 antibodies were from Cayman Chemical (Ann Arbor, MI) and BD
Biosciences.
Plasmids constructions. For assessment of human iNOS and human COX-2
binding, complete coding regions, verified by DNA sequencing, were cloned into the
pcDNA3.1 vector according to manufacturer’s instructions (Invitrogen).
Immunoprecipitation assays. Coimmunoprecipitation experiments were done
according to Kim et al, (5). Briefly, 5 x 106 A549 cells were plated in 75 cm2 culture
dishes. Cells were induced by Il-1β and IFN-γ at 10 ng/ml of each for 18 h or cotransfected with 15 µg pcDNA3.1-COX-2 and 15 µg pcDNA3.1-iNOS according to the
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manufacturer’s protocol and cultured for 48h. Cells were collected and lysed in lysis
buffer as described (5). Supernatants were precleared with sepharose A/G resin, then
incubated with COX-2 or iNOS antibodies at 4°C overnight. Protein A-sepharose was
then added and mixed by rotation for 1h at 4°C. Resin was washed three times with lysis
buffer at 10-fold bed volume following which the resin was boiled in protein sample
buffer and immunoprecipitates were analyzed by Western blot.
Western blot. For immunoblot analysis of COX-2 and iNOS protein, total
protein (15 µg) from cells was resolved on 8% or 10% SDS-polyacrylamide gels,
transferred to nitrocellulose membrane, and probed with COX-2 or iNOS primary
antibodies (1:2,000) for a minimum of 1 h at 4°C. Blots were then processed with
appropriate secondary antibodies (1:2,000) followed by development in
chemilumenescent reagent (PerkinElmer Life Sciences, Boston, MA ). Densitometry of
images captured on X-Ray film (PerkinElmer Life Sciences) was performed using the
AlphaImage 2000 Documentation and Analysis System (Alpha Innotech, San Leandro,
CA).
Radioimmunoassay (RIA) of COX-2 activity. A549 cells (1 x 106) seeded in
10 cm2 culture dishes were induced or co-transfected as described above. In some cases,
iNOS specific inhibitor, 1400w, was added to media concomitant with Il-1β and IFN-γ
treatment or transfection of COX-2 and iNOS plasmid. For stimulation with NO, 100µM
GSNO was added for 3h prior to cell harvesting. Cells were washed twice in serum free
F-12 media and incubated with arachidonic acid (1 ml, 30 µM) for 15 minutes at 37°C.
Supernatants were assayed for COX activity by RIA for PGE2 as previously described
(7). Four independent assays were done in quadruplicate.
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Results
Analysis of ectopically expressed COX-2 and iNOS in HEK293T cells, Hela
and A549 cells. To measure whether human COX-2 and iNOS interact as detected by
co-immunoprecipitation, each was expressed individually or together in HEK293T, Hela,
and A549 human cell lines. Ectopically expressed proteins were measured 48h after
transfection by Western blot analysis (Fig. 2-1).
Immunoprecipitation of COX-2 in cells over-expressing both COX-2 and iNOS
pulled down COX-2 but not iNOS regardless of the human cell system used to express
these proteins (Fig. 2-1). However, the amount of COX-2 pulled down by the COX-2
antibody (from BD Biosciences) used by Kim et al. to demonstrate COX-2-iNOS
interaction was only about 2% of the level of COX-2 pulled down by a COX-2 antibody
from Cayman Chemical (Fig. 2-2, lane 2 and lane 3). Antibodies from both sources were
used in subsequent immunoprecipitations of COX-2 to measure iNOS interaction.
Immunoprecipitation of iNOS was attempted with the antibody used by Kim et al. to
assess COX-2-iNOS interaction, and a protein of the appropriate molecular weight for
iNOS was very faintly detected (Fig. 2-2, lane 3). However, this protein was also
detected when probed with an anti-COX-2 antibody, suggesting that it is due to a nonspecific antibody interaction.
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Fig. 2-1. Ectopic overexpression and coimmunoprecipitation assays of COX-2 and iNOS in
HEK293T (1a), Hela (1b) and A549cells (1c, 1d). COX-2 was immunoprecipitated by COX-2 polyclonal
antibody from Cayman Chemical (Cox-2-IP-c) and BD Biosciences (Cox-2-IP-b). Western blots were
probed by iNOS antibody (upper panels of Figs. 1a, 1b, and 1c) and COX-2 monoclonal antibody (lower
panels of Fig 1a, 1b, and 1c). The anti-COX-2 antibody reported by Kim failed to immunoprecipitate
COX-2 (Cox-2-IP-b in Fig 1a). The Cayman Chemical antibody, in contrast, immunoprecipitated COX-2
and an immunoreactive protein was observed in the region of ~118 KDa when the blot was probed with
anti-iNOS sera (Figs 1a, 1b, and 1c). This band, however, appears to be a non-specific protein that is
detected by either the iNOS or COX-2 antibodies used to probe the immunoblot and which utilized a
common secondary antibody (Lanes 3 and 7 from the right in Fig. 1d). Arrows indicate iNOS and COX-2
and an asterisk indicates the non-specific band.
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Analysis of interaction between cytokine-induced COX-2 and iNOS in
ScupT1 and A549 cells. To control for artifacts that could occur in protein processing or
subcellular localization due to ectopic overexpression, COX-2 and iNOS interaction was
also evaluated in two human cell systems where these two proteins are coinducible.
COX-2 and iNOS expression is strongly induced in A549 lung carcinoma cells after
treatment with IL-1β/LPS/ IFNγ at 10 ng/ml for 18 h (Fig. 2-2, lane 1) and occurs to a
lesser extent in ScupT1 lymphoma cells following the same treatment. When
immunoprecipitation was done on induced cells from these two systems, as described
above for transfected cells, COX-2 but not iNOS was pulled down by COX-2 polyclonal
antibody (Fig. 2-2), and no iNOS immunoprecipitation was observed using anti-iNOS
antisera (Fig. 2-2a, lane 4).

Fig. 2-2. Expression and coimmunoprecipation assays of COX-2 and iNOS in cytokine-induced A549
and ScupT1 cells. COX-2 was immunoprecipitated by COX-2 polyclonal antibody from Cayman
Chemical (Cox-2-IP-c) and COX-2 antibody from BD Biosciences (Cox-2-IP-b) in A549 cells (2a) and
Scup T1 cells (2b). INOS was immunoprecipitated by iNOS antibody from BD Biosciences. Western
blots were probed by iNOS polyclonal antibody (upper panel in 2a and 2b) and COX-2 monoclonal
antibody (lower panel in 2a and 2b).
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The effects of GSNO and 1400w on cytokine-induced COX-2 activity in A549
cells. The NO donor, GSNO, indiscriminately stimulates COX-1 and COX-2 activity via
nitrosylation (7) whereas the iNOS inhibitor, 1400w, was reported by Kim et al. to
specifically attenuate COX-2 activity. The latter effect was postulated to be due to
prevention of nitrosylation of cysteine 526 through direct interaction between iNOS and
COX-2 (5). Cytokine-induced A549 cells contain high levels of induced COX-2 and
iNOS (Fig. 2-3) but lack detectable COX-1 and, therefore, were used to detect the effects
of these agents on COX-2 activity. Assays were done in the presence of exogenous
arachidonic acid to saturate COX-2 enzyme in order to measure the total catalytic activity
of the enzyme. Treatment with GSNO (100 µM) for three hours had no effect on COX-2
expression and caused a modest increase in COX-2 activity in the presence of exogenous
arachidonic acid (30 µM) as expected (Fig. 2-3, lane 2, 3, 5). However, rather than
diminishing COX-2 activity in the presence of exogenous arachidonic acid as anticipated,
treatment with 1400w (100 µM) also caused a slight increase in COX-2 activity similar to
GSNO. Also, when 1400w was coadministered with GSNO, a slight increase in COX-2
activity was observed similar to that caused by treatment with GSNO alone. Thus, in the
presence of exogenous arachidonic acid, 1400w had no inhibitory effect on cytokineinduced COX-2 activity in A549 cells (Fig. 2-3, lanes 4-5).
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Fig. 2-3. The effect of exogenously generated NO and iNOS inhibition by 1400w on cytokine-induced
COX-2 activity. A549 cells were activated by Il-1β and IFN-γ at 10 ng/ml for 18 h with the presence of
1400w (100 µM). GSNO, exogenous NO donor, was included in media for three hours before 30 µM
arachidonic acid in fresh media was added and PGE2 was measured. Data were pooled from four
independent determinations, each done five times (T-test, *P<0.05; **P<0.001).

The effects of GSNO and 1400w were also measured on PGE2 synthesized from
endogenous arachidonic acid in cytokine-induced A549 cells to determine whether the
mode or level of arachidonic acid delivery to the enzyme affected the action of these
agents. A modest non-statistical increase in activity was seen for GSNO-treatment;
however, 1400w produced a significant decline in enzyme activity that was not prevented
by co-treatment with GSNO (Fig. 2-4).
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Fig. 2-4. Effect of GSNO and 1400w on COX-2 activity utilizing endogeonous arachidonic acid in
cytokine stimulated A549 cells. A549 cells were activated by Il-1β and IFN-γ at 10 ng/ml for 18 h in the
presence of 1400w (100µM). GSNO, exogenous NO donor, was added to media for three hours before the
media was collected for PGE2 RIA analysis. Data were pooled from four independent determinations, each
done five times (T-test, *P<0.05; **P<0.001)

Inhibition of recombinant human COX-2 activity by 1400w in sf9 insect cells.
The fact that 1400w had no effect on COX-2 activity in the presence of high levels of
exogenous arachidonic acid, but inhibited COX-2 activity utilizing endogenous
arachidonic acid, suggested that 1400w may be an inhibitor of COX-2 at the high
concentration (100 µM) used in these experiments. COX-2 inhibitors may act either at
the COX active site or by affecting the redox state of the enzyme and can be outcompeted by high levels of substrate, which also alter the enzyme’s redox state by the
generation of prostaglandin peroxides. Tested against human COX-2 expressed
recombinantly in insect cells, 1400w was found to be an inhibitor of COX-2 at
concentration as low as 10 µM if 1µM arachidonic acid is applied (Fig. 2-5). The fact
that 1400w did not entirely inhibit COX-2 activity may represent different

45

subpopulations of glycosylated forms of COX-2 overexpressed in Sf9 cells, only one of
which is inhibited by 1400w.

Fig. 2-5. Inhibition of COX-2 activity by 1400w. The effects of 1400w on COX-2 activity were tested in
Sf9 cells overexpressing human COX-2. COX-2 activity was measured by the formation of PGE2 after
exposure to exogenous 5µM or 1µM arachidonic acid (AA) for 10 min. Data are expressed as
mean ± SEM (n = 3).

The effect of GSNO and 1400w on ectopically expressed COX-1 and iNOS
activity. The studies of Kim et al. suggested that iNOS interaction was specific for the
COX-2 isozyme and not for COX-1. We tested this by overexpression of human iNOS
and human COX-1 in A549 cells in the presence of exogenous arachidonic acid. As with
COX-2 measured in the same system (Fig. 2-2), COX-1 activity was stimulated by
1400w and was not inhibited (Fig. 2-6).
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Fig.2-6. The effect of exogenously added NO and 1400w treatment on ectopically expressed COX-1
activity. A549 cells were co-transfected by COX-1 and iNOS and cultured for 48 h in the presence of
1400w (100µM). GSNO, exogenous NO donor, was added to media for three hours before 30 µM
arachidonic acid in fresh media was exposed to cells for ten minutes and PGE2 measured. Data were
pooled from four independent determinations, each done five times (T-test, *P<0.05; **P<0.001)

Discussion
Nitric oxide from NOS isozymes and prostaglandins from cyclooxygenases can
function to regulate similar or opposing physiological processes. In the cardiovascular
system, in particular, expression of prostaglandins and nitric oxide requires coordination
to properly influence vascular tone. Moreover, both enzyme systems contain highly
inducible members (COX-1 and iNOS) that are co-induced in some contexts. Together
these facts raised the question of whether there is “cross-talk” between iNOS and COX-2
(9). Some investigators found that NO could down-regulate COX-1 and COX-2 catalytic
ability (10), whereas others found that it stimulated it (8). In both cases, the effect of NO
was not specific for either COX isozyme and was presumed to occur through the action
of cell-diffusible NO and not through specific transfer of NO to COX through NOS-COX
interaction.
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Recently, Kim et al. reported that iNOS binds to COX-2 in induced mouse
RAW264.7 cells and transfected human HEK293T cells. In their transfection studies
they ectopically co-expressed human COX-2 and murine iNOS, or used recombinantly
altered forms of these enzymes. In the present studies we tested ectopically expressed or
cytokine induced human COX-1 and human iNOS in a variety of human cells lines, but
found no evidence for direct interaction of human iNOS and human COX-2. The
discrepancy between the results of the two studies may lie in species differences of the
cell systems used (murine versus human), or the fact that we paired human COX-2 and
iNOS as opposed to murine iNOS and human COX-2 in their cell system. It is possible
that, for unknown reasons, murine iNOS somehow can translocate into the ER to bind to
COX-2 in murine and human cells, while human iNOS cannot. Alternatively, nonspecific interaction may occur between the two proteins following solubilization of the
ER membrane. These possibilities, however, remain to be demonstrated.
In the course of these studies we identified a number of variables that could result
in an artefactual interpretation of iNOS-COX-2 interaction. One regards antibodies used
for co-immunoprecipitation experiments. Although we used the immunoprecipitation
procedure of Kim et al. exactly as described, we found that both the COX-2 and iNOS
antibodies employed only weakly precipitated their cognate proteins. Moreover, in our
coimmunoprecipitation experiments where iNOS antibodies were used to probe
immunoblots containing proteins pulled down by anti-COX-2 sera, we always observed a
detected protein that migrated in SDS-PAGE in the region of iNOS (Fig. 2-1, lane 3 and
Fig. 2-2 lane 3). The protein, however, does not exactly migrate with iNOS and also is
present when the blot was probed with COX-2 antibody (Fig. 2-1d), which makes us
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believe it is not iNOS but a nonspecific protein present in the COX-2 antibodies used for
immunoprecipitation.
Another phenomenon we observed was that 1400w weakly stimulated COX-2
catalytic activity in over-expression assays, rather than inhibiting activity as found by
Kim et al. These ectopic co-expression assays were done using exogenous arachidonic
acid substrate and a relatively short exposure time to 1400w (3 hours). In contrast, PGE2
produced in cell media using endogenous arachidonic acid as substrate was found to be
detectably inhibited in the presence of 1400w (Fig. 2-5) as shown by Kim et al. One
possibility for this result, as proposed by Kim et al., is that 1400w inhibits COX-2
activity by preventing COX-2 nitrosylation, since 1400w inhibits NO synthesis dose
dependently. However, the fact that the high levels of 1400w used in these studies (100
uM), weakly inhibit the activity of COX-2 expressed in Sf9 cells in vitro (Fig. 2-5) and
that GSNO, a strong NO donor, failed to stimulate the production of PGE2 in the
presence of 1400w in induced A549 cells provides an alternative explanation that the
inhibition of 1400w on the PGE2 produced from endogenous substrates is due to weak
direct weak inhibition of COX-2 by 1400w. This is further indicated by the fact that
PGE2 production in cytokine induced A549 cells was not lower than vehicle-treated cells
when 1400w was removed before exdogenous arachidonic acid incubations, even though
the cells were treated with 1400w for 18 hours (Fig. 2-3).
As previously noted, iNOS is made as a cytosolic protein which, under some
conditions, can translocate to a subdomain in perinuclear membrane containing misfolded
or aggregated proteins called the aggresome, where it is likely faces the cytosol (11). The
COX-2 isozyme, on the other hand, is in the lumen of the endoplasmic reticulum (ER).
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At best, this places COX-2 and iNOS on opposite sides of membranes where they could
not interact. COX-2 is directed into the lumen of the ER by its N-terminal signal peptide
encoded by exon 1 of the gene. Exons 2 and 3 encode the EGF dimerization module and
membrane binding domains respectively (12). Almost all of the recombinantly altered
forms of COX-2 employed by Kim et al. in their pull-down assays had their exon-1
region deleted, thus producing COX-2 variants that will no longer translocate into ER and
will be cytosolic. Interpretation of iNOS interaction based on those constructs should be
interpreted with caution. Other constructs employed by Kim et al. involved removal of
all or part of exons 1-3, which will not only make COX-2 cytosolic but also is predicted
to produce proteins that are monomers and non-membrane binding. These forms are
very different in structure than COX-2 in vivo and pull-down assays with anti-iNOS
antibody may not reflect in vivo interactions.
Regardless of these findings that failed to find a direct interaction between
human iNOS and COX-2, we did observe that NO weakly stimulated COX-2 activity
when exogenous arachidonic acid was applied to cytokine-induced A549 cells. As
shown by others previously, this implies that NO can modulate COX-2 catalytic activity
at least to some extent. However, in human cells this appears to be through celldiffusable NO, not through direct iNOS and COX-2 binding. This effect of NO is also
not specific for COX-2 as shown by the fact that ectopically expressed COX-1 activity in
A549 cells was equally stimulated (Fig. 2-6). Kim et al. noted that COX-1 and iNOS do
not bind to each other, further underscoring the fact that this action of NO occurs through
diffusion. The activation of both COX-1 and COX-2 by NO makes sense because
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cysteine 526, shown by Kim et al. to be the important nitrosylation site in COX-2
necessary for activation, is also highly conserved in COX-1.
Our studies find NO to be a weak stimulator of COX activities, with COX-1 and
COX-2 activity only increasing about 15% following treatment of 100 µM GSNO when
the enzyme is measured at near Vmax. Thus drugs designed for the purpose of blocking
nitrosylation of COX-1 or COX-2 activity may not be effective at reducing inflammation
or other unwanted processes where these enzymes are involved.
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CHAPTER 3
Putative in-frame human COX-3 variants produce structurally and catalytically
distinct COX isozymes
Abstract
Cyclooxygenases (COXs) are of important therapeutic value as they are the target
site of aspirin-like drugs. A catalytically active COX-1 splice variant in dog, COX-3, has
been reported that retains intron 1. The same transcript occurs in humans; however,
intron 1 is out of frame producing a frameshift and nonsense protein. Two putative inframe human COX-3 transcripts, COX-1b2 and COX-1b3, (herein designated as COX-372 and COX-3-50) have been reported in the literature, but the encoded protein of only
one of them, COX-3-72, has been characterized. This study analyzes COX-3-50 protein
and compares it with COX-3-72. When COX-3-72 and COX-3-50 were over expressed
in insect and mammalian cell systems, these proteins differed in their pattern of Nglycosylation, protein stability and enzyme activity. COX-3-50 was unstable and was
more poorly expressed, yet was more than ten times more active than COX-3-72.
Moreover, COX-3-72, and to a greater extent, COX-3-50, were stimulated by treatment
with rofecoxib at physiological concentrations. A similar rofecoxib-stimulated COX
activity is observed in quiescent A549 cells. Immunoblot and immunoprecipitation
analysis suggest that human platelets and potentially A549 cells contain a COX-3-50 like
protein. Polymerase chain reaction analysis of A549 transcripts shows that this protein
does not occur by RNA editing but by some other process, such as ribosomal
frameshifting. Our data, together with previous published results, suggest the existence
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of one or more COX-3 proteins in humans which could be activated by rofecoxib at
physiological concentrations.
Introduction
Cyclooxygenases (COXs) are encoded by two genes: COX-1 and COX-2. COX-1
is constitutively expressed, whereas COX-2 is largely inducible (1,2). Recent work has
led to the identification of a canine COX-1 splice variant, termed COX-3 that retains
intron 1. COX-3 produced a novel active enzyme when ectopically expressed in insect
cells. This enzyme was found to be inhibited by NSAIDs and analgesics such as
acetaminophen and dipyrone better than mouse COX-1 and COX-2 (2). Acetaminophen
is often used for analgesic and anti-pyretic purposes because it causes fewer
gastrointestinal problems than commonly used NSAIDs (1).

Human COX-3 mRNA is transcribed at readily detectable levels in heart, brain,
kidney, liver, skeletal muscle, stomach, and small intestine as well as in various subregions of human brain (2, 3). However the existence of human COX-3 protein remains
questionable since intron 1 of human COX-1 is 94 nt in length and its complete retention
would shift the frame of the encoded protein (2, 3, 4, 5). Although human COX-3 is out
of frame, some immunoprecipitation assessments suggest the existence of COX-3 protein
in human tissues (2).

Two types of in-frame COX-3 mRNAs have been recently reported in the
literature (3, 6). They retain the intron 1 but are missing either a guanine at position 72
(COX-3-72) or a cytosine at position 50 (COX-3-50). Thus, these two COX-3 transcripts
contain a self-rectifying shift in the reading frame, which allows the translation of a full
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length COX protein in Sf9 cells. Single nucleotide polymorphisms (SNP) and RNA
editing have been proposed as mechanisms to explain the correction of frame in these
COX-3 transcripts (2, 3). Only ectopically expressed human COX-3-72 has been
characterized at the protein level, and was demonstrated to possess most of the structural
and catalytic properties of canine COX-3 (3). Notable differences were that human
COX-3-72 was more catalytically active than canine COX-3 and less sensitive to
analgesic/antipyretics and some NSAIDs (3). Here we compare human COX-3-50,
COX-3-72 and COX-1 proteins and demonstrate that the position of the self-rectifying
frameshift significantly influences the structural and catalytic properties of the resulting
COX-3 variant produced. Furthermore, our research, together with our previous results
(2), indicates the existence of one or more endogenous COX-3 proteins in human
platelets and possibly A549 cells. Additionally, over-expressed COX-3-50 and COX-372 are activated by the COX-2 selective drugs rofecoxib (Vioxx) and (to a lesser extent)
celecoxib (Celebrex). Rofecoxib was withdrawn from the market because of an
increased risk of cardiovascular problems, the reasons for which are still not well known.
We postulate that rofecoxib’s ability to stimulate a COX-3 activity in the vascular
system, particularly in platelets, could be responsible for increased risk of cardiovascular
adverse events in humans.
Materials and Methods
Ectopic expression of COX-1, COX-3-50 and COX-3-72 variants in Sf9 cells.
For ectopic expression and assessment of enzyme activity of COX-3 in Sf9 cells,
complete coding regions, verified by DNA sequencing, were cloned into the baculovirus
expression vector pBlueBac 4.5/V5-His according to manufacturer’s instructions
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(Invitrogen). For analysis of protein expression, Sf9 cells (~1 × 106) were infected with
viral stocks at a multiplicity of infection (moi) of 3 (2).
In some cases, to assess N-glycosylation of individual splice variants,
tunicamycin was added at a final concentration of 10 µg/ml to insect cells 1 h after
infection. Cells were then cultured and harvested after 48 h. The level of recombinant
protein expression was determined by immunoblot analysis, and COX activity in intact
cells was determined by radioimmunoassay (RIA) (2).
For immunoblot analysis of protein expression, total protein (20 µg) from cells
was resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose
membrane, and probed with COX-1 mAb as described above.
Drug inhibition assays and Vmax and Km determinations. Sf9 cells were
infected with high titer viral stocks (moi of 3) and cultured for 48 h to express COX-1,
COX-3-50, or COX-3-72. Cells were pelleted by centrifugation and washed in serum
free-media, after which the level of ectopically expressed protein was evaluated by
immunoblot. Cell numbers were then adjusted so that equal amounts of COX isozymes
and enzyme activity were used in subsequent drug inhibition assays. For these assays,
cells were preincubated with test compounds for 30 min at 25°C and arachidonic acid
(final concentration, 30 µM) was then added for an additional 10-min incubation at 37°C.
Cells were then pelleted and the supernatant was removed and assayed for COX activity
by RIA of PGE2. For each test compound, assays were performed multiple times in
triplicate, inhibition curves were constructed, and IC50 values were determined using
PRISM 3.0 (GraphPad, San Diego).
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For Vmax and KM determinations, initial velocities were determined by stopping
cyclooxygenase enzyme reactions by transferring reaction tubes into boiling water 15
seconds after the addition of arachidonic acid. This length of time for substrate
incubation was determined by doing time-course assays for each COX isozyme
preparation.
Production of polyclonal anti-COX-3 antibodies. Polyclonal anti-COX-3
antibody corresponding to the N-terminal 13 amino acids of COX-3-50 and COX-3-72
(MSRECDPGARWG) was previously made in our laboratory (2). Another antibody
directed against the last 12 amino acids (LSPSSLSSAGSL) of the intron-1 encoded
sequence contained in COX-3-50 and COX-3-72 was generated. The cognate peptide
was coupled to keyhole limpet hemocyanin as carrier and injected into rabbits. The
antibody against N-terminus COX-3 isozymes is designated H1253, and the antibody
against C-terminal end of the intron-1 encoded sequence in these enzymes is designated
K0040.
In some cases antibody was purified by coupling the cognate peptide to Sulfolink
coupling gel (Pierce) according to the manufacturer’s instructions. Serum (15 ml) was
applied to the resin and incubated overnight after which the resin was washed and bound
antibodies were eluted in glycine buffer (pH 2) and equilibrated to pH 7.4.
Detection of COX-3-related proteins cells by Western blotting. Total protein
(20 µg) from A549 cells or platelet preparations was analyzed by Western blotting using
murine COX-1 mAb (Cayman Chemical, Ann Arbor, MI) and rabbit COX-3 antipeptide
polyclonal antibodies (pAb). Blots were processed with appropriate anti-mouse
secondary antibody (1:2,000) or anti-rabbit secondary antibody (1:10,000) from Sigma.
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Densitometry of X-ray film-captured luminescent images was performed using the
AlphaImage 2000 Documentation and Analysis System (Alpha Innotech, San Leandro,
CA).
Detection of 71- and 72-kDa COX-3-related proteins in human platelets by
immunoprecipitation. For immunoprecipitation experiments of COX-3, human
platelets were collected and homogenized. Microsome fractions were prepared and
solubilized in ice-cold lysis buffer (100 mM Tris pH 7.4, 150 mM NaCl, 10% glycerol,
1% Triton X-100, and protease inhibitor cocktail). The supernatants (800 µl) were
precleaned for nonspecific binding with 50 µl protein A–Sepharose, then mixed overnight
at 4ºC with COX-3 antibody (H1253). After the addition of 80 µl of protein A–
Sepharose, the immunoprecipitates were mixed for another 1 hour at 4ºC. The mixture
was washed three times with the buffer described above. The pellet was then boiled in 10
µl SDS-loading dye containing β-mercaptoethanol. The released protein was loaded on
to a 10% SDS PAGE gel, electrophoresed, transferred to nitrocellulose membrane, and
probed with murine COX-1 mAb (Cayman Chemical) at 1:2,000 dilution overnight at
4°C. Blots were then processed with rabbit-anti-mouse secondary antibody (1:2,000)
from Sigma. Densitometry of the autoradiographic images were with AlphaImage 2000
Documentation and Analysis System.
RT-PCR amplification, and DNA sequencing. Isolation of RNA has been
described (7). Human cDNA was synthesized from mRNA isolated from A549 cells by
reverse transcription-coupled polymerase chain reaction (RT-PCR). To analyze for
COX-3-50 and COX-3-72 expression, primers were specifically designed for
amplification of the COX-1 intron 1 region. The sense primer (5'-
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CTGCGTCCCGCACCCCAGCA-3') corresponded to nucleotides -20 to -8 of the human
COX-1 sequence. The antisense primer (5'- CCGGAGCAAGAGACTCCCTGCAGA 3') included five nucleotides of the C-terminal intron 1 and 19 nucleotides of the Nterminal exon 2. Amplicons were cloned into pCR3.1-TOPO and transformed in
competent E. coli (Invitrogen) and verified by DNA sequencing.
Results
Over-expression of Human COX-3-50 and COX-3-72 in Sf9 cells and
measurement of enzyme activity. COX-3 mRNA in mammalian species is defined as
the COX-1 mRNA that additionally retains intron-1 and, in some species, also possesses
a significantly longer 3’ untranslated region (2, 3). Retention of intron-1, which is 94
nucleotides in length in human COX-3 mRNA, would introduce a frame-shift and
produce a non-sense protein. However, human COX-3-50 and COX-3-72 forms of this
sequence have been reported that exhibit postulated RNA editing events which remove
single nucleotides in the intron-1 portion of COX-3 mRNA at positions 50 or 72,
respectively (3). These deletions produce a self-rectifying shift in the reading frame that
will potentially produce functional COX-1 related isozymes that retain their signal
peptides plus 31 amino acids encoded by intron 1. The predicted amino acid sequences
of the 31 amino acids encoded by intron-1 of COX-3-50 and COX-3-72, which differ by
only 6 internal residues, are shown in Figure 3.1.
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Fig. 3-1. N-terminal protein sequence of COX-1, COX-3-50 and COX-3-72. Exons 1 and 2 of
the COX-1 gene encode the N-terminal hydrophobic signal peptide. Thus retention of intron1 results in
sequence inserted into the signal peptide of COX-1. The blue and black sequences represent amino acids
encoded by intron 1and sequence highlighted in red is of the N-terminal signal peptide. Amino acids
highlighted in black represent residues that differ between COX-3-50 and COX-3-72. Antibody used in
these studies against the N-terminal amino acids of intron 1 is designated H1253 and antibody against Cterminal amino acids of intron 1 is designated K0040.

COX enzymes are intralumenal residents of the endoplasmic reticulum and depend
on N-linked glycosylation for proper folding and activity. Retention of intron 1
theoretically could prevent COX-3-50 and COX-3-72 expression by preventing export of
these mRNAs from the nucleus or by targeting these proteins to another subcellular
compartment, preventing glycosylation. To test if these COX-3 proteins are properly
expressed, Sf9 cells were infected with recombinant baculovirus expressing COX-1,
COX-3-50 and COX-3-72 and cell homogenates were assayed for protein expression by
Western blotting. COX-1 mAb and H1253 were used to probe for COX-3-50 and COX3-72.

This analysis demonstrated that both COX-3-50 and COX-3-72 are expressed in
insect cells, although COX-3-72 is expressed at much higher levels than COX-3-50 (Fig. 3
-2a). COX-3-50 and COX-3-72 are glycosylated on asparagine similar to COX-1, as
this glycosylation can be prevented by tunicamycin treatment (Fig. 3-2a, lower). Like
canine COX-3, the signal peptide was also retained in COX-3-50 and COX-3-72, since
these proteins were detected by H1253 (Fig. 3-2a, lower, lane 2-4 and Fig. 3-2b, lane 460

5). Retention of the first 15 nucleotides of intron 1, which are highly conserved in
mammalian species, are sufficient to prevent cleavage of the signal peptide (Fig. 3-2b,
middle, lane 3).
Purified and unpurified preparations of H1253 were used in our analyses and
produced the unexpected finding that unpurified COX-3 antibody detected COX-3-50
significantly better than COX-3-72 and purified antibody produced the opposite result
(Fig. 3-2b, upper, lane 3-4). None of these preparations detected COX-1 (Fig. 3-2b, lane
2), suggesting that unpurified and purified H1253 preparations recognize different
conformational epitopes specific for COX-3-50 and COX-3-72, respectively.
Conformational/structural differences between COX-3-50 and COX-3-72 were
further evidenced by the fact that COX-3-50 was expressed much more poorly than
COX-3-72, COX-1 or its variant that retained 15 nucleotides. It also consistently
exhibited an abundance of distinct apparent proteolytic break-down products not shared
with the other COX proteins. Treatment with tunicamycin additionally showed that
although all the COX proteins are N-linked glycosylated, the COX-3-50 protein showed
an altered pattern of N-linked glycosylation relative to the other COX forms. COX-3-50
also differed with the other COX proteins in its level of cyclooxygenase activity. Despite
the fact that COX-3-50 is expressed much more poorly than COX-3-72, it was found to
be at least 10-fold more active than COX-1 and COX-3-72 (Fig. 3-2a, upper, lane 3)
when account is taken of the differing levels of protein expression. Determinations of KM
and Vmax for COX-3-50 and COX-3-72 isozymes were performed that further
demonstrated this difference (Fig. 3-2c). Although COX-3-50 enzyme was present in this
assay at a level that was estimated by immunoblot to be only one fifth that of COX-1 and
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COX-3-72, it had a Vmax value double that of COX-1 and significantly greater than
COX-3-72. In contrast, the KM values for COX-3-50 and COX-3-72 were determined to
be half that of COX-1 (Fig. 3-2c), suggesting greater affinity for substrate.

Fig. 3-2. COX-3 over expression in insect cells. 2a. Western blots showing the expression of COX-1,
COX-3-15, COX-3-50 and COX-3-72 in insect cells treated with (+) (lower, right )and without (-)
tunicamycin (lower, left). Arrows indicate glycosylated forms of COX-1 that are not present in cells
treated with tunicamycin. Murine monoclonal antibody to ovine COX-1 (Cayman Chemical) was used to
probe the blot. Because of the low level of expression of COX-3-50, five times more cellular protein was
loaded in the gel to enable viewing. The upper panel shows COX activity in insect cells expressing COX1, COX-3-15, COX-3-50 and COX-3-72. The same amount of cellular protein was used in each assay.
Cells in the upper and lower panel were treated with (+) and without (-) tunicamycin as described in
Materials and Methods. 2b. Western blot showing the retention of signal peptide in COX-3. COX-3
antibodies in unpurified serum, affinity purified anti-COX-3 preparations (see Materials and Methods), and
COX-1 monoclonal antibody were used to probe COX-1, COX-3-15, COX-3-50 and COX-3-72 on the
blot. 2c. KM and Vmax value of COX-1, COX-3-15, COX-3-50 and COX-3-72 were determined by RIA.
Cyclooxygenase KM and Vmax values were determined by measuring the activity in the presence of 0.9330 µM arachidonic acid and fitting the values to the Michaelis-Menten equation by using Kaleidagraph
software (Synergy Software). Data were expressed as mean ± SEM (n = 3)

62

Inhibition of COX-3-50 and COX-3-72 by NSAIDs, acetaminophen and
coxibs. Canine COX-3 differs from COX-1 in sensitivity toward some NSAIDs and
analgesics (2). Therefore, common analgesic/antipyretic drugs and NSAIDs were tested
for their ability to inhibit activity of human COX-1, COX-3-50 and COX-3-72. Analyses
were done in the presence of exogenously added AA at 30 µM concentrations. Neither
COX-3-50 nor COX-3-72 was appreciably inhibited by acetaminophen. The COX-3-72
protein, in fact, exhibited a modest dose-dependent trend toward stimulation (Fig. 3-3).
Human COX-1 and COX-2 are similarly affected by this drug (data not shown).
However, COX-3-50 and COX-3-72 were inhibited by NSAIDs such as ibuprofen where
they demonstrated only slight differences in comparison to COX-1 (Fig. 3-3). An
exception was aspirin, which preferentially inhibited COX-3-72 over COX-1 and COX3-50 by about 7-fold. The increased sensitivity toward aspirin was previously reported
for canine COX-3 (2) and COX-3-72 by Qin et al (1). Analysis of coxibs produced the
unexpected finding that COX-3-50, but not COX-3-72 or COX-1, were stimulated with
very low concentrations of rofecoxib (<1µM [Fig. 3-3]). At higher concentrations,
(>1µM) a much more modest stimulation of COX-1 and COX-3-72 was also observed.
The overall results indicate that COX-3-50 and COX-3-72 possess COX activity that
differs pharmacologically from COX-1 and COX-2.
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Fig. 3-3. Drug inhibition studies. The effects of acetaminophen, aspirin, celecoxib and rofecoxib on
COX-1 (black), COX-3-50 (pink), and COX-3-72 (blue) activity in Sf9 cells. COX activity was measured
by the formation of PGE2 after exposure to exogenous 30µM arachidonic acid for 10 min. Data are
expressed as mean ± SEM (n = 3).

Analysis of COX-3 expression in A549 cells. The human lung carcinoma line
A549 has been used extensively in studies of COX because it is highly inducible for
COX-2 expression by a variety of cytokines and mitogens. Quiescent cells also contain a
low-basal level of an uncharacterized COX activity that is presumed to be related to
COX-1. Western blotting analysis of human A549 cells by two COX-3 antipeptide
polyclonal antibodies detected the presence of distinct 65- and 72-kDa putative COX-3

64

proteins (Fig. 3-4). H1253, developed against N-terminal sequence of intron 1, detected
both 65- and 72-kDa bands, whereas K0040, developed against C-terminal sequence of
intron 1, detected only the 65-kDa protein. The 65-kDa protein detected by H1253 was
more prominent than K0042 which may suggest that the binding efficiency of H1253 is
better than K0042, and could account for why the 72-kDa protein was not detected by
K0040.

Fig. 3-4. Western blot on A549 cells. COX-3 polyclonal antibodies raised against the N-terminal
(H1253) and C-terminal (K0040) protein sequence of intron 1 in immunized rabbit serum were used to
probe the blot. Two immunoreactive proteins were detected by H1253 and one was detected by K0040 as
indicated by arrows.

Analysis of COX-3 expression in human platelets. Human platelet is a rich
source of COX-1 protein and a potential source for COX-1 splice variants. Western
blotting analysis of human platelets (Fig. 3-5) detected the presence of 65-, 71-, and 72kDa COX-3 bands by using two COX-3 antibodies as done for A549 cells (above).
When platelet protein was subjected to an immunoprecipitation pull-down assay (done by
Lamar Roos) using H1253 or its pre-immune antisera as the antibody, 71- and 72-kDa
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proteins detected by anti-COX-1 antisera were pulled down by the former but not the
latter (Fig. 3-5b).

Fig. 3-5. Western blotting and immunoprecipitation assays of putative COX-3 proteins in human
platelets. 5a: H1253 (lane 1-2), K0040 (lane 3-4) and COX-1 (lane 5-6) monoclonal antibodies were used
as primary antibodies for development of Western blots which detected 65-, 71-, and 72-kDa putative
COX-3 related proteins denoted by arrows. Human COX-1 transfected in COS-7 cells was used as positive
control (lane 1,3 and 5). 5b: H1253 was used to pull down potential COX-3 proteins from human platelet
lysate. COX-1 monoclonal antibody (mAb) was used as primary antibody to develop the Western blot.
Lane 1 is canine COX-3 used for molecular weight comparison. Lane 2 and 3 are human platelet COX-1
as detected in two different patients. Lane 4 shows two COX-3 related proteins (designated by an arrow) in
the immunoprecipitate brought down by H1253 COX-3 antibody. Lane 5 is the immunoprecipitate brought
down by a 2-fold excess of pre-immune serum. Densitometry of the image was performed using an
AlphaImage 2000 Documentation and Analysis System (Alpha Innotech, San Leandro, CA).
Immunoprecipitation experiment was by Lamar Roos.
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Modulation of cyclooxygenase activity in A549 cells by rofecoxib. The finding
in A549 cells of proteins ~72,000 Da in size by the H1253 antibody raised the possibility
that these cells expressed a low level of a COX-3-like protein. The antibody used in this
experiment was unpurified, which reacts primarily with the COX-3-50 form of COX-3
(Fig 3-2b). This form also is selectively stimulated by rofecoxib (Fig. 3-3). Therefore,
COX activity in non-stimulated, quiescent A549 cells was measured in the presence and
absence of rofecoxib, celecoxib, and indomethacin as control. The IC50 value for COX2 inhibition in these cells by rofecoxib was determined to be 0.17µM (data not shown).
In quiescent cells, this highly selective COX-2 inhibitor inhibited 40% of COX activity in
A549 cells at 1µM (Fig. 3-6a, lane 1-2), likely due to residual expression of COX-2
under these cell-culture conditions. With increasing levels of rofecoxib (5, 10 and 50µM)
stimulation of PGE2 production was observed. Celecoxib and indomethacin, in contrast,
did not demonstrate this stimulatory effect and both agents inhibited COX activity to a
greater extent than rofecoxib. Previous experiments by Lamar Roos also generated
stimulation by rofecoxib of COX activity, but to a greater extent than seen in our studies
(Fig. 3-6b). In the Roos’ studies, cells may have been more quiescent and thus contained
lower levels of interfering COX-2 expression.
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Fig. 3-6. A549 cells Rofecoxib stimulation assays. 6a: The effects of rofecoxib, celecoxib and
indomethacin on A549 cell COX activity. COX activity was measured by the formation of PGE2 after
treatment with the drugs for 30 minutes followed by exposure to exogenous 30µM arachidonic acid for 10
minutes. Data are expressed as mean ± SEM (n = 3). 6b: The effects of rofecoxib on quiescent A549 cells
as done by Lamar Roos. COX activity was measured after rofecoxib treatment as described in 6a.
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Assessment of RNA editing of intron 1 in COX-3 transcripts from A549 cells.
The COX-3-50 and COX-3-72 isoforms have been reported to result by either RNA
editing or because of the presence of single-nucleotide polymorphisms (SNPs) in intron
1. The finding in A549 cells of a putative COX-3 immunoreactive protein and a
rofecoxib stimulated COX activity, suggested the presence of a COX-3 isoform in these
cells. To evaluate this possibility, RNA was extracted from quiescent A549 cells and
measured for the presence of COX-3 mRNA, which was readily detected (data not
shown). This mRNA was then evaluated for the presence of single-nucleotide deletions
that would occur if either RNA editing or SNPs were present. To do this, 5 independent
PCR amplifications were performed to generate amplicons spanning the COX-3 intron 1
region. These amplicons were individually cloned into pCR3.1-TOPO, transformed into
competent E. coli, and 10 clones from each of the five amplicons were purified and
sequenced. No single nucleotide deletions were detected.
Discussion
The data above suggest that COX-3-72 and COX-3-50, two in-frame COX-3
reported in the literature, differ structurally and enzymatically, despite the fact that their
only difference is six amino acids located in the intron 1 region. By Western blot
analysis, non-purified H1253 COX-3 antibody preferred binding to COX-3-50 while
affinity purified H1253 preferred COX-3-72 (Fig. 3-4), suggesting that the intron-1
region can form at least two alternative stable conformations. Because the protein was
electrophoresed through a denaturing gel this conformation would likely result from
refolding of the small domain containing the sequence of the cognate peptide used to
develop the antibody. Other tell-tale signs of structural difference included the low level
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of expression of COX-3-50 in Sf9 cells relative to the other COX-1 related proteins
examined. Furthermore, COX-3-50 was different from the other forms in its distinctly
different pattern of its breakdown products and pattern of glycosylation (Fig. 3-2a).
Retention of the signal peptide with an embedded intron-1-encoded sequence represents
an addition of over 50 amino acids to the amino terminus of the protein and could
understandably have significant structural effects as a result. These effects could be
evoked either by altering subcellular localization or kinetic or thermodynamic properties
of folding. However, it is intriguing that COX-3-72 differs little in its expression level or
glycosylation pattern with either COX-1 or another variant that contains only 15
nucleotides of intron 1. Yet COX-3-50, which differs from COX-3-72 by only 6 internal
residues encoded by intron 1 is so dramatically affected by this small change.
The COX-3-50 and COX-3-72 are not only different structurally, but are also
different in their cyclooxygenase catalytic activities. Despite being poorly expressed,
COX-3-50 is significantly more active than COX-1 or any of its variant forms we have
thus far examined. It is also significantly more active than COX-2 (data not shown).
This high activity may answer a question regarding COX-3 mRNA expression in
humans, which is frequently found at lower levels (~10%) than that of COX-1.
Expression of a low level enzyme with high catalytic activity could result in a
physiologically significant pool of COX enzyme activity. Moreover, this pool of enzyme
activity would be difficult to detect in comparison to COX-1.
The retention of the signal peptide and intron-1 encoded sequence to the amino
terminus of COX-3-50 and COX-3-72 appears to also result in steric changes that affect
either or both cyclooxygenase and peroxidase active sites in the enzyme. Most noticeable
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was the finding of increased sensitivity toward aspirin in COX-3-72 (Fig. 3-3) and
stimulation of COX-3-50 and COX-3-72 by the coxibs celecoxib and refocoxib. The 2fold stimulation by rofecoxib of COX-3-50 when measured at Vmax may be significant
from a medical viewpoint. Stimulation of this COX isoform occurred at concentrations
well below at 1µM, which is peak plasma level of this drug under normal dosing
regimens in vivo.
COX-2 enzyme inhibitors were developed based on the hypothesis that selective
inhibition of COX-2 would decrease pain and inflammation without associated
gastrointestinal and bleeding risks (1). However, rofecoxib (Vioxx) and valdecoxib
(Bextra), two COX-2 inhibitors were withdrawn from the market due to excess
cardiovascular risk in 2004 and 2005. The withdrawal of rofecoxib and valdecoxib raises
great concern about cardiovascular side effects of COX-2 inhibitors and other NSAIDs
which inhibit both COX-1 and COX-2. Very few data have been published regarding the
reason of this increased risk. Suppression of prostacyclin (PGI2) but not thromboxane A2
biosynthesis by coxibs is a popular theory to explain this increase (8). Our data provide
an alternative to this hypothesis and suggests that not all COX-2 inhibitors may have a
negative cardiovascular impact.
Because the human COX-3 mRNA has been shown to be highly expressed in the
vascular system, including in the heart and microvasculature of the brain (2, 3, 9),
persistent stimulation of this activity could create a proinflammatory state in the
vasculature resulting in atherosclerosis, a condition considered by many investigators to
be a form of inflammation (10). Alternatively stimulation of COX-3 activity in platelet
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could theoretically increase thromboxane A2 synthesis, thus increasing thrombotic events
leading to myocardial infarction or stroke.
Thus, our finding may explain the cardiovascular risks associated with rofecoxib
use and may also allow the testing of other coxibs, non-selective NSAIDs, or other drugs
with regard to their ability to stimulate COX-3 and thus potentially negatively impact the
cardiovascular system.
Our finding of potential COX-3 proteins in human platelets and A549 cells is
problematic given that we found no evidence for either SNPs or RNA editing that could
result in correction of the reading frame shift generated by intron-1 insertion in COX-3.
However, analysis of the intron-1 sequence demonstrates a canonical slippery site for -1
ribosomal frame-shifting five codons upstream from the COX-3-50 deletion site. This
sequence, GGGGAATTTTCTT, conforms exactly to the viral sequences for -1 ribosomal
framsehsifting and may provide a mechanism by which a COX-3-50 like protein is made
in humans (11). Further studies, including characterization of COX-3 sequence in human
platelets and A549 cells, are needed in order to fully prove the existence of COX-3 in
humans, to define its catalytic roles, and to determine how the protein is made.
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CHAPTER 4
Trifunctional inhibition of COX-2 by extracts of Lonicera japonica: direct
inhibition, transcriptional and post-transcriptional down regulation.
Abstract
The anti-inflammatory properties of aqueous extracts from Lonicera japonica
(LJ) flower, an anti-inflammatory treatment in traditional Chinese medicine, were tested
by radioimmunoassay of cyclooxygenase isoenzyme-generated prostaglandin E2 (PGE2)
synthesis as well as by Western and Northern blot analysis of COX-2 protein and mRNA
expression, respectfully. Boiled LJ aqueous extracts directly inhibited both COX-1 and
COX-2 cyclooxygenase activity, while non-boiled extracts stimulated both enzymes.
Boiled LJ extracts also inhibited expression of IL-1β-induced COX-2 protein expression
and suppressed its mRNA induction by IL-1β in A549 cells. Suppression of COX-2
mRNA induction required a significantly higher dose of aqueous extract than did
suppression of protein expression, indicating that compounds in the extract act
translationally or post-translationally at lower doses and transcriptionally or posttranscriptionally at higher doses. Direct inhibition of COX isoenzymes as well as downregulation of COX-2 mRNA and protein may represent the mechanism by which this
ancient herbal treatment decreases inflammation.
Introduction
The aqueous extract from Lonicera japonica (LJ) flower has been used in Chinese
traditional medicine for treating fever, arthritis and infectious diseases for thousands of
years. Previous studies have shown that LJ could act as an anti-inflammatory agent
through regulation of NF-қB activation, since it inhibits the appearance of nuclear NF-қB
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p65 and the action of I-қB in the liver of lipopolysaccharide (LPS) challenged rats (1).
LJ has also been found to inhibit LPS induced inflammatory responses such as induction
of tumor necrosis factor (TNF-α) and inducible nitric oxide synthase as well as by
inhibiting PAR2 agonist induced myeloperoxidase activity in paw tissue (2).
Cyclooxygenase (COX) isoenzymes, COX-1 and COX-2, promote inflammation
through the production of prostaglandins (3). Whereas COX-1 is constitutive, COX-2 is
highly inducible and is readily elevated in tissues in response to proinflammatory stimuli,
including cytokines and bacterial LPS (4). COX-2 converts arachidonic acid to
prostaglandin H2, which is then further metabolized to various prostaglandins,
prostacyclin, and thromboxane A2 (3). Thus, COX-2 is thought to be the isoform
responsible for the production of proinflammatory prostanoids in many models of
inflammation (4). COX-2 over-expression is also seen in human malignancies including
colorectal cancer, lung cancer, and breast cancer (5). COX-2 selective NSAIDs have
been used to inhibit intestinal neoplasia in mice and human (6).
Whether the analgesic and anti-inflammatory effects of LJ can be attributed to
inhibition of COX-2 activity or expression has not been previously examined. Here we
show that LJ can either directly stimulate or inhibit COX-1 and COX-2 activity,
depending on how the extract is made. Moreover, boiled LJ extract down-regulates
COX-2 by two mechanistically distinct pathways.
Material and Methods
Reagents. Dried Lonicera japonica flower bought from a local health food store
was boiled in phosphate buffered saline (PBS) for 5 minutes to yield boiled aqueous
extracts or stirred at 4 °C overnight to get non-boiled aqueous LJ extracts. IL-1β was
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purchased from Sigma. Penicillin, streptomycin, F-12 nutrient mixture and Grace’s
insect medium were obtained from Invitrogen. Fetal bovine serum (FBS) was from
Hyclone and polyclonal and monoclonal COX-2 antibodies were purchased from
Cayman Chemical.
Cell lines and culture. A549 lung carcinoma cells were maintained in F-12
nutrient mixture with 10% FBS. Sf9 insect cells were grown in Grace’s insect medium
supplemented with 10% FBS. Culture media contained 100U/ml penicillin and 100ug/ml
streptomycin.
Expression of human COX-1 and human COX-2 in baculovirus-infected
insect cells. For radioimmunoassay (RIA), human COX-1 and human COX-2 coding
regions, verified by DNA sequencing, were cloned into the baculovirus expression vector
pBlueBac 4.5/V5-His (Invitrogen). Recombinant plaques were identified, purified and
high titer viral stocks were prepared following the protocol of the manufacturer. Sf9 cells
(5 × 106) were infected with viral stocks at a multiplicity of infection (moi) of 3. COX-1
and COX-2 expression was determined by RIA of prostaglandin E2 using intact cells and
by Western blot of cell lysates.
LJ Cyclooxygenase Inhibition Assays. Sf9 cells were infected with
recombinant baculovirus encoding human COX-1 or COX-2 and cultured for 48 h. Cells
(2 × 105, 100µl) were suspended in serum free medium and preincubated with LJ extracts
(50µl) for 30 min at 25°C. Arachidonic acid (final concentration of 30 µM in a final
volume of 200µl) was then added for an additional 10-min incubation at 37°C. Cells
were pelleted by centrifugation and assayed for COX activity by RIA of PGE2. A
minimum of three independent assays for each isoenzyme and each drug preparation
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were performed and each was done in triplicate. Inhibition curves were constructed and
IC50 values were determined using PRISM 3.0 (GraphPad, San Diego, USA).
Western blot analysis. Total protein (15 µg) from cells was resolved by SDSpolyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane and probed
with COX-2 or actin primary antibodies (1:2,000) for a minimum of 1 h at 4°C. Blots
were processed with appropriate secondary antibodies (1:2,000). Densitometry of the
autoradiographic image was performed using an AlphaImage 2000 Documentation and
Analysis System (Alpha Innotech, San Leandro, CA).
Northern blot. Total RNA was isolated from cell cultures using the RNeasy kit
(Qiagen, Valencia, CA, USA). Five micrograms of total RNA was separated on a 1.0%
agarose gel containing formaldehyde and RNA was transferred to membrane and crosslinked by UV light. Prehybridization was performed in QuickHyb solution (Stratagene,
La Jolla, CA, USA) for 1h at 65°C. Human COX-2 and GAPDH cDNA probes were
labeled with [32P]-CTP using random priming and hybridized to the blots overnight at
65°C. Blots were washed twice in 2 x SSC with 0.01% of SDS and exposed to X-OMAT
Blue XB-1 film (Kodak, Rochester, NY, USA) for autoradiography. Film images were
recorded and analyzed using AlphaDigiDoc (Alpha Innotech, CA, USA).
Results
Cytotoxicity of LJ extract to A549 cells. Cytotoxicity of LJ boiled and nonboiled extracts to A549 cells was measured by trypan blue assay. Cell viability was not
significantly affected by LJ extracts up to concentrations of 100 mg/ml (data not shown).
Concentrations of LJ extracts below this threshold were used in subsequent experiments.
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LJ extracts inhibit COX-1 and COX-2 Prostaglandin E2 (PGE2) synthesis.
Boiled LJ and non-boiled extracts were tested for their ability to inhibit prostaglandin
synthesis activity of COX-1 and COX-2. In Sf9 cells, PGH2 produced by COX-1 and
COX-2 non-enzymatically rearranges to PGE2. Thus analysis of PGE2 directly assesses
COX activity. Analyses of human COX-1 and COX-2 over-expressed in Sf9 cells were
done at Vmax for the enzymes by adding exogenously arachidonic acid at 30µM
concentrations.
Prior to analyses, boiled and non-boiled extracts were evaporated to dryness and
solutes were collected and weighed. Solutes were then redissolved in water at 0.2g : 1ml
and diluted to specific concentrations. Both COX-1 and COX-2 were inhibited by boiled
LJ extracts (Fig. 4-1 top), while non-boiled LJ extracts greatly stimulated COX-1 and did
not inhibit COX-2 (Fig. 4-1 bottom). Moreover, COX-2 was more sensitive (by
approximately four fold) to boiled LJ extracts than COX-1 (Fig. 4-1). Boiled LJ extracts
inhibited COX-2 with an IC50 value of 15 mg/ml, whereas IC50 values for COX-1 were 56
mg/ml.
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Fig. 4-1. Inhibition of PGE2 synthesis by LJ aqueous extracts. The effects of boiled LJ extracts and
non-boiled extracts on COX-1 ( ), and COX-2( ) activity in insect cells. COX activity was measured by
the formation of PGE2 after exposure to exogenous 30 µM arachidonic acid for 10 min. Data are expressed
as mean ± SEM (n = 3-5).

Boiled LJ extracts inhibit IL-1β-induced COX-2 protein expression.
Activation of COX-2 is one of the critical events mediating inflammation (3). Therefore,
LJ extract’s effect on COX-2 mRNA and protein expression following IL-1β treatment
was investigated. A549 cells were treated with various concentrations of boiled LJ
extracts during induction of COX-2 by treatment with IL-1β (5 ng/ml for 3 h). Treated
cells were divided into two aliquots and analyzed for COX-2 protein by Western blot and
mRNA expression by Northern blot, respectively. Boiled LJ extracts alone did not induce
or repress baseline COX-2 protein expression (Fig. 4-2). However, IL-1β-induced COX-
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2 protein expression was inhibited by boiled LJ extracts in a dose dependent manner (Fig. 4
-2). The IC50 value for COX-2 protein down-regulation was 5.0 mg/ml.

Fig.4-2. Effect of boiled LJ extracts on IL-1β induced COX-2 protein over-expression. A549 cells
were treated with boiled LJ extracts and IL-1β for 3 h. Whole cell extracts were resolved on SDS-PAGE
and transferred to nitrocellulose membrane. Western blot was done using COX-2 and actin antibodies as
described in Materials and Methods.

Boiled LJ extracts down regulate IL-1β-induced COX-2 mRNA
transcription. Northern blot analysis was carried out to evaluate COX-2 mRNA
expression in A549 cells treated with various concentrations of LJ extracts in the
presence or absence of IL-1β as described above. Induction of COX-2 mRNA was
observed after exposure to IL-1β for 3 h (Fig. 4-3, lane 3). No significant inhibition of
COX-2 transcription occurred at 5.4 or 16.2 mg/ml of extract, a concentration at which
COX-2 protein was strongly down-regulated (Fig. 4-3, lane 4 and lane 5). However, at
54 mg/ml, COX-2 mRNA was completely down regulated. The degree of down
regulation observed was comparable to that evoked by 20 µM dexamethasone (Fig. 4-2,
lane 6 and lane 7), a known down regulator of COX-2 mRNA transcription and message
stability.
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Fig. 4-3. Effect of boiled LJ extracts on IL-1β induced COX-2 mRNA transcription. A549 cells were
treated with LJ boiled extracts and IL-1β for 3h. A549 cells treated with 20 µM dexamethasone (DEX) and
IL-1β were used as a positive control for transcriptional down-regulation and COX-2 mRNA
destabilization. Total cellular RNA was isolated; 5 µg of RNA was added to each lane. The Northern blot
was probed sequentially for COX-2 mRNA and GAPDH.

Discussion:
The current study investigated the effect of LJ aqueous extracts on inhibition of
cyclooxygenase activity and COX-2 expression. Boiled LJ extract inhibits both COX-1
and COX-2 activity, favoring COX-2 inhibition by four fold. This boiled extract, the
method by which LJ tea is made in China, contains endogenous NSAID-like compounds.
The identity of these is unknown, but salicin and other salicylate derivatives have long
been known to exist in willow bark and other plants. Boiled LJ extract could be an
effective NSAID because it shows preferential inhibition toward COX-2. It would not
likely have the gastric sparing properties of highly selective COX-2 inhibitors, such as
rofecoxib, but it may not possess the reported cardiovascular risks that have been
reported for this drug (11).
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In contrast to boiled extracts, non-boiled extract actually stimulates COX-1
activity. A number of organic compounds, such as acetaminophen at some doses, do the
same (7). Stimulation by non-boiled LJ is likely due to the presence of phenolic or other
compounds that can act as co-reductants in the COX enzymatic redox cycle (3). We
postulate that boiling in air may oxidize these compounds.
In addition to containing NSAID-like compounds, boiled extract down-regulates
COX-2 mRNA expression. Previously, the aqueous extract from Lonicera japonica
flower was shown to inhibit NF-қB activation through reducing I-қB degradation (1).
Ochnaflavone, a natural biflavonoid isolated from Lonicera japonica Thunb., was found
to inhibit LPS induced iNOS expression through NF-қB in RAW264.7 cells (8). COX-2
is frequently co-induced with iNOS in RAW264.7 cells (9). Thus although unexamined
in this study on ochnaflavone, COX-2 may also have been down-regulated since Il-1β
induced COX-2 expression is also known to involve NF-қB. The COX-2 transcriptional
inhibition capacity of boiled LJ extracts seen in our studies may be due to biflavonoids or
structurally similar compounds acting through NF-қB.
Boiled LJ extract also inhibited COX-2 protein expression at lower doses than
those that produce inhibition of COX-2 mRNA expression. COX-2 protein induction
was inhibited by 60% and 90% at 5.4mg/ml and 16.2mg/ml while COX-2 mRNA was not
detectably inhibited at those two concentrations. These findings suggest that boiled LJ
extract also contains compounds which inhibit COX-2 post-transcriptionally. Only one
other known natural product, radicicol, is known to have this effect (10). Purified from
the culture broth of fungus strain KF9, radicicol has a variety of clinically important
medical uses, including as an antibiotic, anti-inflammatory and anti-tumor agent. It
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inhibits c-src tyrosine kinases in lipopolysacharide-stimulated macrophages. The active
gradients in LJ could function the same as radicicol or be structurally and functionally
different. However, the compounds in LJ may have similar therapeutic potential in
inflammation and neoplasia.
In summary, the data show the existence of three different compounds in LJ
which directly, transcriptionally and post-trancriptionally inhibit COX-2 to potentially
decrease inflammation. Since COX-2 is one of the most critical proteins related to
inflammation, the inhibition of COX-2 by LJ extracts represents a potential therapeutic
approach to the treatment of inflammatory diseases.
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CHAPTER 5
Studies on the N-terminus of COX-1 and its effect on cyclooxygenase-1 catalytic
activity
Abstract
Cyclooxygenases (COX) are encoded by two genes: COX-1 and COX-2. Even
though COX-1 and COX-2 in all species share only sixty percent sequence identity they
are very similar to each other in their crystallographic structures. One difference in the
primary structure of these two isozymes is the presence of eight amino acids in the
amino-terminal region of COX-1 that are not present in COX-2. This amino acid
sequence, in fact, forms the amino terminus of the processed COX-1 protein following
cleavage of the signal peptide and its function is unknown. In this study, a human COX1 deletion variant with this sequenced removed was constructed, transfected into
mammalian cells, and studied in parallel with human COX-1. No differences were
observed in N-linked glycosylation or in the level of expression of the mutant relative to
COX-1. The mutant was enzymatically active as determined by radioimmunoassay and
showed the same sensitivity toward aspirin as COX-1. However, whereas the KM for the
enzyme remained the same as COX-1, its apparent Vmax decreased four fold. We
conclude that the COX-1 specific amino-terminal sequence has a subtle but detectable
effect on COX-1 catalysis.
Introduction
Cyclooxygenases (COX) are rate-limiting enzymes in the production of
prostaglandins from arachidonic acid (1). Two isoforms of this enzyme exist in many
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species: COX-1 and COX-2. COX-1 is constitutively expressed while COX-2 is highly
inducible in response to a variety of agents including pro-inflammatory cytokines and
mitogens. Both COX-1 and COX-2 have a molecular weight of approximately 71K and
are 63% identical in sequence (2). COX-1 and COX-2 share the same four functional
regions: an amino-terminal signal peptide, dimerization domain, membrane binding
domain, and catalytic domain (3). Crystallographic structures show a striking tertiary and
quaternary structural similarity between COX-1 and COX-2 (4, 5).
In spite of this structural similarity, COX-1 and COX-2 exhibit differences in
sensitivity towards different NSAIDs. The difference is the result of a change in one of
the 24 amino acid residues which line the hydrophobic cyclooxygenase active site - Ile at
position 523 in COX-1 and Val at position 523 in COX-2. A mutation of Ile 523 to Val
in the COX-1 enzyme makes it sensitive to COX-2-selective inhibitors and site-directed
mutation of Val 523 to Ile in COX-2 shows inhibitor binding comparable to that seen in
COX-1 (6, 7, 8). The Ile/Val substitutions result in pharmacological and biochemical
differences between COX-1 and COX-2 that have permitted the development of COX-2
selective inhibitors (coxibs).
Based on primary sequences alone, the major differences between COX isoforms
occur at the amino and carboxy terminal ends. COX-1 has 8 amino acids inserted at its
amino terminal end not found in COX-2 and COX-2 has 18 amino acids inserted in its
carboxyterminal region not found in COX-1 (9, 10). The effect of deleting the18 amino
acids in the COX-2 carboxyl terminus has been investigated by others (11). The role of
the additional 8 amino acids in the amino-terminal end of COX-1 is unknown. This
sequence begins at the +1 position relative to the N-terminal hydrophobic signal peptide
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cleavage site. Co-translational cleavage of the signal peptide results in this sequence
being located at the amino terminus of the processed protein, immediately upstream of
the dimerization domain of the COX-1 protein (3).
In this study, a human COX-1 deletion mutation that removes almost all of this
amino-terminal sequence was constructed and studied in parallel with COX-1.
Specifically, the COX-1 deletion mutant differed from full length COX-1 only in deletion
of seven of the eight amino acids immediately following the signal peptide cleavage site.
The eighth residue, a valine (Val 32) was retained in order to keep a hydrophobic residue
at the N-terminus of the process protein. The results suggest that the deletion of the
seven amino acids coding sequence does not affect COX-1 expression in mammalian
cells nor the enzyme’s sensitivity towards aspirin. However, the seven amino acid
deletion decreases the apparent Vmax of the enzyme.
Materials and Methods
Materials. COX-1 monoclonal antibody was obtained from Cayman Chemical
(Ann Arbor, MI). Arachidonic acid, Tween-20 and all other reagents were obtained from
Sigma-Aldrich if not designated otherwise.
Construction of the COX-1 deletion mutation (∆7aa). Human COX-1 in
pcDNA 3.1 vector was used as a template. The following primers were designed for
PCR amplification to make the 21 nucleotide deletion mutation: the sense primer (5'ATGAGCCGGAGTCTCTTGCTCTGGTTCTTGCTGTTCCTGCTCCTGCTCCCGCCG
CTCCCCGTCCTGCTCGCGGACAATCCCTGTTGTTACTATCCATGCCAGCAC-3')
corresponded to nucleotides 0 to 126 from human COX-1 sequence with a 21 nucleotide
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deletion; and the antisense primer (5'TCAGAGCTCTGTGGATGGTCGCTCCACAGCA-3') corresponded to nucleotides
1768-1799, which are begin 31 nucleotides upstream of the COX-1 stop codon and
continue to the stop codon. For ectopic expression and assessment of enzyme activity of
∆7aa and COX-1, coding regions were cloned into linearized pCR3.1-TOPO vector
(Invitrogen). Plasmids were isolated and sequenced to assure that the proper mutation
was made without the introduction of other unwanted changes.
Transfection of COX-1 and ∆7aa into COS-7, CHO, HEK239T and
A549cells. COX-1 and ∆7aa cloned into the pcDNA3.1 vector were transiently
transfected into COS-7 cells using lipofectamine with Plus Reagent (Invitrogen). Cells,
harvested 48 h post-transfection by scraping, were washed once with PBS prior to being
counted in a hemocytometer. In some experiments equal numbers of cells from
transfection experiments were solubilized in protein sample buffer for immunoblot
analysis. In other instances, as designated in figure legends, cell protein was quantified
by Bio-Rad Protein Assay (Bio-Rad) and equal amounts of protein were compared on
immunoblots. To measure transfection efficiency, COX-1 and ∆7aa constructs were
cotransfected with a transfer vector containing a cDNA encoding firefly luciferase. Cell
aliquots of these co-transfected cells were lysed and measured for luciferase activity by
luminometry.
To measure N-glycosylation of COX variants in mammalian cells, tunicamycin
was added to cells to a final concentration of 10 µg/ml 4h after transfection. Cells were
then cultured for an additional 48 h.
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Immunoblot analysis of ∆7aa and COX-1 expression. For immunoblot analysis
of protein expression, total protein (20 µg) from cells was resolved by SDSpolyacrylamide gel electrophoresis, transferred to nitrocellulose membrane, and probed
with COX-1 murine mAb (Cayman Chemical). Primary antibodies (1:2,000) were
incubated with membranes overnight at 4°C. Blots were processed with appropriate
rabbit-anti-mouse secondary antibody (1:2,000) from Sigma. Densitometry of images
was performed using the AlphaImage 2000 Documentation and Analysis System (Alpha
Innotech, San Leandro, CA).
Radioimmunoassay (RIA) measurement of cyclooxygenase activity of COX-1
and ∆7aa. Transfected cells (0.1 x 106 cells; 100 µl) were incubated with arachidonic
acid (final concentration 30 µM) for 15 minutes at 37°C. Supernatants were assayed for
COX activity by RIA for PGE2 as previously described (12). Three separate assays were
performed for every protein analyzed and each was done in triplicate.
Aspirin inhibition assay. For measurement of irreversible inhibition of the COX
active site by aspirin, transfected cells were mixed and incubated with aspirin for 30 min
at 25°C. The mixture was then incubated with arachidonic acid (final concentration,
30 µM) for an additional 15 minutes at 37°C. Supernatants were assayed for COX
activity by RIA for PGE2. At least three separate assays were performed for every
protein analyzed and each was done in triplicate.
Determining KM and Vmax value of COX-1 and ∆7aa. KM and Vmax were
determined by both oxygen uptake and RIA. Oxygen uptake was assayed
polarographically at 37°C as described previously (13). One unit of cyclooxygenase
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activity has an optimal velocity of 1 nmol of O2/min. For determination of KM and Vmax
values by RIA, arachidonic acid (30 µM) was added to cells and the cyclooxygenase
enzyme reaction was stopped after 15 seconds by transferring reaction tubes into boiling
water. Cyclooxygenase KM and Vmax values were determined by measuring
prostaglandin synthesis activity in the presence of 0.93-30 µM arachidonic acid and
fitting the values to the Michaelis-Menten equation by using Kaleidagraph software
(Synergy Software).
Results
Construction of the COX-1 deletion mutation (∆7aa). The PCR products
amplified from human COX-1 containing the desired mutations were inserted into the
pcDNA3.1 vector. The integrity of the resulting transfer vector constructs was verified
by restriction enzyme digestion and DNA sequencing. Shown in figure 5-1, are the Nterminal eight amino acids (bold style) of COX-1 not found in COX-2. The eight amino
acids are located between the signal peptide (italic style) and the dimerization domains
(regular style) of COX-1.

Fig. 5-1. N-terminal sequence of human COX-1, COX-2 and ∆7aa. N-terminal sequence of COX-1,
COX-2 and ∆7aa are shown. The signal peptide is in italics. Residues in regular font are the beginning of
the COX dimerization domain and residues in bold are the eight amino acids of HCOX-1 not present in
HCOX-2.
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Detection of COX-1 and ∆7aa over expressed in mammalian cells.
Polyacrylamide gel electrophoresis and subsequent visualization by immunoblot of the
transfected cells revealed a major band at ~72 kDa for native COX-1 and the ∆7aa
mutant. Comparison of the degree of expression of each protein showed that COX-1
and the ∆7aa mutants were expressed to similar levels in mammalian cells systems (Fig. 5
-2). Transfected CHO and HEK293 cells produced more COX-1 and ∆7aa mutant
protein than COS-7 and A549 cells (Fig. 5-2). This result was due to different
transfection efficiencies as shown by co-transfection with a luciferase reporter gene
(data not shown). In all cell lines examined, ectopically expressed ∆7aa protein
migrated slightly faster than COX-1 in SDS PAGE, reflecting the deletion of aminoterminal sequence or alteration of posttranslational modification. The smaller size of
∆7aa protein also indicated that removal of sequence adjoining the signal peptide
cleavage site did not prevent co-translational signal peptide removal.

Fig. 5-2. COX-1 and ∆7aa protein expression in mammalian cells. Western blots showing the
expression of HCOX-1 and ∆7aa in COS-7, CHO, HEK293 and A549 cells. Equal amount of protein
(15ug) from lysate were electrophoresed on each lane. A monoclonal antibody to ovine COX-1 (Cayman
Chemical) was used to probe the COX-1 and ∆7aa blot.
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Other than cleavage of the signal peptide, the only other known posttranslational
modification of COX-1 is N-linked glycosylation. Because of the size difference noted in
Fig 5-3, as well as the importance of N-linked glycosylation in governing proper COX-1
folding and activity, the glycosylation state of COX-1 and ∆7aa mutant was measured in
the presence and absence of tunicamycin. As in the previous experiment, ∆ 7aa was
smaller than COX-1 in the presence and absence of tunicamycin, indicating that this size
difference is due to the deletion of the 7 amino acids and not an effect on
posttranslational modification (Fig. 5-3). However, the size difference observed is about
1.3 KDa, which is slightly larger than the calculated size of the deleted seven amino acids
(0.6 KDa) (Fig. 5-3).

Fig. 5-3. COX-1 and ∆7aa over-expression in A549 and COS-7 cells in the presence and absence of
tunicamycin. Ectopically expressed COX-1 and ∆7aa in A549 and COS-7 cells treated with (+) and
without (-) tunicamycin were measured by immunoblotting with anti-COX-1 mAb used a probe.
Immunoreactive proteins are indicated by arrows. Because of unequal transfection efficiencies between
cell types, the levels of proteins have been adjusted so that they are similar in each lane.

Radioimmunoassay (RIA) on Cyclooxygenase activity of COX-1 and ∆7aa.
To assess the effects of the ∆7aa mutation on cyclooxygenase catalysis, we measured
92

cyclooxygenase activity for both proteins in the presence of 30µM exogenous
arachidonic acid. In each assay, the COX activity in one hundred thousand transfected
cells was measured and each assay was repeated 5 times. By this method he ∆7aa mutant
was found to produce equal amounts of PGE2 as COX-1. Furthermore, the PGE2 made
from the ∆7aa mutant and native COX-1 was significantly higher than that produced by
cells transfected with a control plasmid (**P< 0.001) (Fig. 5-4).

Fig. 5-4. RIA analysis of PGE2 formed by COX-1 and ∆7aa. Radioimmunoassay of PGE2 produced by
ectopically expressed COX-1and ∆7aa in COS-7 cells was performed with COS-7 cells transfected with
pcDNA3.1 empty vector used as negative control. Immunoblot analysis was done to assure that equal
amounts of COX-1 and ∆7aa were used in the RIA (lower panel). Data are expressed as mean ± SEM
(n = 5). (**P< 0.001)
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Aspirin inhibition assay. Aspirin covalently acetylates the COX active site and
COX-1 and COX-2, whose COX active sites differ in dimension and contour, exhibit
differences in the ability of aspirin to acetylate them. Therefore, COX-1 and ∆7aa were
compared in their susceptibility to aspirin acetylation. Enzymes were incubated with
various concentrations of aspirin for 30 minutes and were then exposed to exogenously
added arachidonic acid (30µM) and PGE2 measured. COX-1 showed the same sensitivity
to aspirin as ∆7aa (Fig. 5-5).

Aspirin Inhibition
% activity of control

100

7 aa
cox-1

75

50

25

0
0

1

2

3

4

log[aspirin] µM

Fig. 5-5. Aspirin inhibition studies. The effect of aspirin on COX-1 ( ) and ∆7aa ( ) activity in COS-7
cells. Transfected cells were preincubated with aspirin. Activity was measured by the formation of PGE2
after exposure to exogenous 30 µM arachidonic acid. Data are expressed as mean ± SEM (n = 3)

Determining KM and Vmax value of COX-1 and ∆7aa. To assess the effects of
the mutation on cyclooxygenase catalysis, we also measured the KM and Vmax for
arachidonic acid (Fig. 5-6). To enable comparison of the Vmax values obtained in this
assay, cell number was carefully quantified, and equal numbers of transfected cells were
used in each assay. The determination of Vmax of COX-1 was 52.3µM ± 3.92 and Vmax
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of ∆7aa was 15.9 µM ± 0.86. The determination of KM of COX-1 was 1.90 µM ± 0.56
and KM of ∆7aa was 1.55 µM ± 0.35.

Fig. 5-6. Km-Vmax assay of HCOX-1 and ∆7aa. KM and Vmax value of COX-1 and ∆7aa were
determined by oxygen uptake and RIA and gave similar results. Only the RIA determined value is shown
here. Cyclooxygenase activity was measured with 1.9-30 µM AA and values were fit to the MichaelisMenten equation. Data are expressed as mean ± SEM (n = 3)

Discussion:
The aim of the current study was to investigate the function of eight amino acids
unique to COX-1 which compose the amino-terminal end of the fully processed protein.
Removal of seven of these eight amino acids produced a catalytically active COX
enzyme that expressed with equal efficiency to COX-1 in four mammalian cell lines.
Removal of the signal peptide was not affected in the deletion mutation as evidenced by
its smaller molecular weight relative to COX-1. However, the size difference between
COX-1 and ∆7aa (1.3K) was larger than expected (0.6K) (Fig. 5-3). Slight aberrancy in
migration is commonly seen in SDS PAGE which could account for this result.
Alternatively, it could result from the removal of an unknown posttranslational
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modification that is located in the removed 7 amino acids. The size difference observed
is not caused by N- glycosylation, since tunicamycin treated cells show the same size
difference as untreated cells. Other possibilities that could theoretically account for this
size difference include phosphorylation or O-glycosylation. Therefore the COX-1
sequence was analyzed in NetOGlyc 3.1 Server which analyzes for potential Oglycosylation sites. Prediction results showed that there could be an O-glycosylation
modification on Thr-30 that was deleted in ∆7aa. However, COX-1 has not yet been
demonstrated to traffic to the Golgi region where this type of modification would likely
occur.
In most respects the polypeptide produced from the deletion mutation was
functionally the same as COX-1. Equal amounts of PGE2 were made from
cyclooxygenase activity of COX-1and ∆7aa in COS-7 cells and both enzymes were
equally sensitive toward aspirin. Kinetically, there is no significant difference between
the KM value for COX-1 and the deletion mutation, but the native COX-1 enzyme had a
Vmax value that was 4-fold higher than that of the mutant, indicating an affect of this
sequence on catalysis. Paradoxically the enzyme activity of COX-1 and ∆7aa in the
presence of near-saturating concentrations of arachidonic acid (30µM) is essentially
identical when measured for 10 minutes (Fig. 5-4). Cyclooxygenases undergo fairly
rapid autoinactivation during catalysis (1). Thus, although ∆7aa exhibits a lower Vmax
than COX-1 when instantaneous velocities are measured, it may be more long lived as a
catalyst.
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Appendix I
Screening large numbers of recombinant plasmids: modifications and additions to
alkaline lysis for greater efficiency
Selecting bacteria transformed with recombinant plasmid is a laborious step in
gene cloning experiments. This selection process is even more tedious when large
numbers of clones need to be screened. We describe here modifications to the ultra fast
plasmid preparation method described previously by Law and Crickmore (1). The
modified method is coupled to an efficient PCR step to rapidly determine orientation of
the inserts. Compared to traditional methods of analysis requiring growth of overnight
cultures, plasmid isolation and restriction enzyme digestion to determine orientation (2)
this procedure allows for the analysis and storage of a large number of recombinants
within a few hours.
Law and Crickmore described a simplified alkaline lysis procedure. Briefly,
recombinant bacterial colonies (~1 mm in size) growing on agar plates are picked into
100µl of pre-warmed lysis buffer (5 mM EDTA, 10% w/v sucrose, 0.25% SDS 100 mM
NaOH, 60 mM KCl and 0.05% bromophenol blue) and incubated at 37°C for 5 min. The
tube is then placed on ice for 5 min followed by centrifugation in a microfuge for 1min.
Supernatant (20 µl) is then electophoresed on an agarose gel, where the electrophoretic
mobility of potential recombinants is compared with a plasmid control (vector without an
insert). Recombinant plasmids typically exhibit slower migration in the gel compared to
vector.
This method requires centrifugation and has the drawback of RNA
contamination resulting from incomplete alkaline hydrolysis. When gels are used with
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multiple rows of wells, this low molecular weight undegraded RNA tends to migrate
through the wells in front of them to mask plasmid DNA (Fig. A-1a). We have found
that pancreatic RNAse is still catalytically active in the alkaline lysis buffer and can be
used to remove this unwanted RNA. This modification also avoids the cumbersome steps
of chilling and centrifugation, greatly shortening the procedure and making it more
useable in microtiter plate format (Fig. A-1b).
To further greatly streamline plasmid isolation, orientation of inserts, and long
term storage of the clones, we use the following process.
Rather than inoculate bacterial colonies directly into lysis buffer (which
requires one to go back to the original plates for further operation), bacterial colonies are
picked into 15µl of phosphate buffered saline (PBS) in Eppendorf tubes containing an
appropriate antibiotic. The bacterial suspension in PBS is mixed well and 10µl is added
to 10µl of our modified lysis buffer (MLB), 10mM EDTA, 20% w/v sucrose, 0.5% SDS,
200mM NaOH, 120mM KCl, 0.1% bromophenol blue and 0.2mg/ml RNAse. This is
simply incubated for 5 min at 37 °C and electrophoresis is performed by the method of
Law & Crickmore. Either during electrophoresis or after identification of recombinant
clones, the orientation of clones is determined by PCR amplifying 1.0µl of the original
bacterial suspension in PBS using two primers, one in the vector and the other in the
insert (Fig. A-2). PCR is done with short extension time (12s) and only clones in the
proper orientation synthesize a product. Because of the short extension time, PCR
amplification (40 cycles) is completed in 1 hour. Desirable clones identified by this
method can then be amplified in large scale cultures by inoculating 1µl bacteria from the
original bacterial suspension in PBS. For long term storage, 200µl of sterile 50%
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glycerol (in LB) is added to the remaining 2-3µl of bacterial suspension in PBS, mixed
well by briefly vortexing, and stored at -80 °C. When a very large number of clones need
to be analyzed the procedure can be carried out in 96 well micro titer plates (Fig. A-1b).
From bacterial colonies to long term storage of analyzed plasmids takes three hours and
the process can be robotically mechanized.

Fig. A-1. Comparison of clones analyzed by Law and Crickmore and modified methods. 1a.
Comparison of bacterial colonies analyzed by the original method (left side lanes 1-16,) and by the
modified method (right side lanes 1-16). Electrophoreses was deliberately done for a short period so that
long smears of low molecular weight of undegraded RNA are observed (on left side of the gel) containing
plasmid DNA isolated by Law and Crickmore. Upon longer electrophoreses to detect mobility difference,
these smears tend to migrate through the wells in front of them to mask the migrating plasmids. Plasmids
on the right are by the modified method. 1b. Clones analyzed by the modified method using 96 well micro
titer plates. Putative recombinant clones were analyzed by the modified method using 96 well plates. For
this procedure the incubation at 4 °C and the subsequent centrifugation step was omitted.
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Fig. A-2. PCR based analysis of recombinant clones. 2a: Recombinant clones that carried an insert
were analyzed by PCR using 1.0µl of the remaining bacterial suspension as the template. Orientation of
the insert was determined by PCR amplifying 1.0µl of the original bacterial suspension in PBS using two
primers, one in the vector and the other in the insert. 2b: An amplicon of 550 bp indicates that the clone is
in the right orientation (lane 1, 3, 4, 5 and 6 of Fig. A-2a). An insert in the reverse orientation will not give
an amplification product (lane 2, Fig. A-2a).
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